{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 3347, "items": [{"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T16:24:40Z", "timestamp": 1574699080811}, "reference-count": 55, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 8, 1]], "date-time": "2015-08-01T00:00:00Z", "timestamp": 1438387200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "bmn.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Current Opinion in Pharmacology"], "published-print": {"date-parts": [[2015, 8]]}, "DOI": "10.1016/j.coph.2015.05.008", "type": "journal-article", "created": {"date-parts": [[2015, 6, 4]], "date-time": "2015-06-04T22:15:26Z", "timestamp": 1433456126000}, "page": "45-51", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 50, "title": ["CSF-1/CSF-1R targeting agents in clinical development for cancer therapy"], "prefix": "10.1016", "volume": "23", "author": [{"given": "Carola H", "family": "Ries", "sequence": "first", "affiliation": []}, {"given": "Sabine", "family": "Hoves", "sequence": "additional", "affiliation": []}, {"given": "Michael A", "family": "Cannarile", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "R\u00fcttinger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Current Opinion in Pharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1471489215000521?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1471489215000521?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 22]], "date-time": "2018-09-22T05:30:00Z", "timestamp": 1537594200000}, "score": 42.40582, "issued": {"date-parts": [[2015, 8]]}, "references-count": 55, "alternative-id": ["S1471489215000521"], "URL": "http://dx.doi.org/10.1016/j.coph.2015.05.008", "ISSN": ["1471-4892"], "issn-type": [{"value": "1471-4892", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "CSF-1/CSF-1R targeting agents in clinical development for cancer therapy", "name": "articletitle", "label": "Article Title"}, {"value": "Current Opinion in Pharmacology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.coph.2015.05.008", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T18:50:56Z", "timestamp": 1575485456745}, "reference-count": 58, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 6, 1]], "date-time": "2014-06-01T00:00:00Z", "timestamp": 1401580800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2015, 6, 16]], "date-time": "2015-06-16T00:00:00Z", "timestamp": 1434412800000}, "delay-in-days": 380, "content-version": "vor"}], "content-domain": {"domain": ["cancercell.org", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Cancer Cell"], "published-print": {"date-parts": [[2014, 6]]}, "DOI": "10.1016/j.ccr.2014.05.016", "type": "journal-article", "created": {"date-parts": [[2014, 6, 2]], "date-time": "2014-06-02T05:43:20Z", "timestamp": 1401687800000}, "page": "846-859", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 419, "title": ["Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy"], "prefix": "10.1016", "volume": "25", "author": [{"given": "Carola\u00a0H.", "family": "Ries", "sequence": "first", "affiliation": []}, {"given": "Michael\u00a0A.", "family": "Cannarile", "sequence": "additional", "affiliation": []}, {"given": "Sabine", "family": "Hoves", "sequence": "additional", "affiliation": []}, {"given": "J\u00f6rg", "family": "Benz", "sequence": "additional", "affiliation": []}, {"given": "Katharina", "family": "Wartha", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Runza", "sequence": "additional", "affiliation": []}, {"given": "Flora", "family": "Rey-Giraud", "sequence": "additional", "affiliation": []}, {"given": "Leon\u00a0P.", "family": "Pradel", "sequence": "additional", "affiliation": []}, {"given": "Friedrich", "family": "Feuerhake", "sequence": "additional", "affiliation": []}, {"given": "Irina", "family": "Klaman", "sequence": "additional", "affiliation": []}, {"given": "Tobin", "family": "Jones", "sequence": "additional", "affiliation": []}, {"given": "Ute", "family": "Jucknischke", "sequence": "additional", "affiliation": []}, {"given": "Stefan", "family": "Scheiblich", "sequence": "additional", "affiliation": []}, {"given": "Klaus", "family": "Kaluza", "sequence": "additional", "affiliation": []}, {"given": "Ingo\u00a0H.", "family": "Gorr", "sequence": "additional", "affiliation": []}, {"given": "Antje", "family": "Walz", "sequence": "additional", "affiliation": []}, {"given": "Keelara", "family": "Abiraj", "sequence": "additional", "affiliation": []}, {"given": "Philippe\u00a0A.", "family": "Cassier", "sequence": "additional", "affiliation": []}, {"given": "Antonio", "family": "Sica", "sequence": "additional", "affiliation": []}, {"given": "Carlos", "family": "Gomez-Roca", "sequence": "additional", "affiliation": []}, {"given": "Karin\u00a0E.", "family": "de\u00a0Visser", "sequence": "additional", "affiliation": []}, {"given": "Antoine", "family": "Italiano", "sequence": "additional", "affiliation": []}, {"given": "Christophe", "family": "Le\u00a0Tourneau", "sequence": "additional", "affiliation": []}, {"given": "Jean-Pierre", "family": "Delord", "sequence": "additional", "affiliation": []}, {"given": "Hyam", "family": "Levitsky", "sequence": "additional", "affiliation": []}, {"given": "Jean-Yves", "family": "Blay", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "R\u00fcttinger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Cell"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1535610814002244?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1535610814002244?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 11]], "date-time": "2019-08-11T05:24:43Z", "timestamp": 1565501083000}, "score": 42.39857, "issued": {"date-parts": [[2014, 6]]}, "references-count": 58, "journal-issue": {"published-print": {"date-parts": [[2014, 6]]}, "issue": "6"}, "alternative-id": ["S1535610814002244"], "URL": "http://dx.doi.org/10.1016/j.ccr.2014.05.016", "ISSN": ["1535-6108"], "issn-type": [{"value": "1535-6108", "type": "print"}], "subject": ["Cell Biology", "Cancer Research", "Oncology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy", "name": "articletitle", "label": "Article Title"}, {"value": "Cancer Cell", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ccr.2014.05.016", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2014 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T20:00:24Z", "timestamp": 1574539224609}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 4, 15]]}, "DOI": "10.1158/1538-7445.am2013-4719", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T23:08:53Z", "timestamp": 1408057733000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 4719: Exploratory biomarker program in Phase I clinical development of RG7155, a novel humanized anti-CSF-1R Mab, targeting Tumor Associated Macrophages (TAMs)."], "prefix": "10.1158", "author": [{"given": "Michael A.", "family": "Cannarile", "sequence": "first", "affiliation": []}, {"given": "Kai", "family": "Habben", "sequence": "additional", "affiliation": []}, {"given": "Florian", "family": "Heil", "sequence": "additional", "affiliation": []}, {"given": "Ann-Marie", "family": "Broeske", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "Ruettinger", "sequence": "additional", "affiliation": []}, {"given": "Lisa", "family": "Culton", "sequence": "additional", "affiliation": []}, {"given": "Friedrich", "family": "Feuerhake", "sequence": "additional", "affiliation": []}, {"given": "Carola H.", "family": "Ries", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 18]]}, "event": {"name": "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC"}, "container-title": ["Immunology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2013-4719", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T20:15:02Z", "timestamp": 1558210502000}, "score": 40.835884, "issued": {"date-parts": [[2013, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2013-4719"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2013-4719"}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T00:47:03Z", "timestamp": 1574556423649}, "reference-count": 9, "publisher": "Informa UK Limited", "issue": "9", "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["OncoImmunology"], "published-print": {"date-parts": [[2014, 9, 2]]}, "DOI": "10.4161/21624011.2014.955356", "type": "journal-article", "created": {"date-parts": [[2014, 10, 29]], "date-time": "2014-10-29T20:07:01Z", "timestamp": 1414613221000}, "page": "e955356", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Targeting tumor-associated macrophages in cancer therapy and understanding their complexity"], "prefix": "10.1080", "volume": "3", "author": [{"given": "Michael A.", "family": "Cannarile", "sequence": "first", "affiliation": []}, {"given": "Carola H.", "family": "Ries", "sequence": "additional", "affiliation": []}, {"given": "Sabine", "family": "Hoves", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "R\u00fcttinger", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 12, 8]]}, "reference": [{"key": "cit0001", "DOI": "10.1016/j.it.2012.08.006", "doi-asserted-by": "publisher"}, {"key": "cit0002", "DOI": "10.1016/j.ccr.2014.05.016", "doi-asserted-by": "publisher"}, {"key": "cit0003", "DOI": "10.1038/ni.1937", "doi-asserted-by": "publisher"}, {"key": "cit0004", "DOI": "10.1371/journal.pone.0050946", "doi-asserted-by": "publisher"}, {"key": "cit0005", "DOI": "10.1016/j.ccr.2013.02.013", "doi-asserted-by": "publisher"}, {"key": "cit0006", "DOI": "10.1084/jem.20130875", "doi-asserted-by": "publisher"}, {"key": "cit0007", "DOI": "10.1186/1479-5876-9-216", "doi-asserted-by": "publisher"}, {"key": "cit0008", "DOI": "10.1016/j.imbio.2013.06.003", "doi-asserted-by": "publisher"}, {"key": "cit0009", "DOI": "10.1111/nyas.12469", "doi-asserted-by": "publisher"}], "container-title": ["OncoImmunology"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.4161/21624011.2014.955356", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 16]], "date-time": "2016-12-16T22:43:26Z", "timestamp": 1481928206000}, "score": 39.20913, "issued": {"date-parts": [[2014, 9, 2]]}, "references-count": 9, "journal-issue": {"published-online": {"date-parts": [[2014, 12, 8]]}, "published-print": {"date-parts": [[2014, 9, 2]]}, "issue": "9"}, "alternative-id": ["10.4161/21624011.2014.955356"], "URL": "http://dx.doi.org/10.4161/21624011.2014.955356", "relation": {"cites": []}, "ISSN": ["2162-402X"], "issn-type": [{"value": "2162-402X", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=koni20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=koni20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T14:06:45Z", "timestamp": 1574690805208}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2014, 10, 1]]}, "DOI": "10.1158/1538-7445.am2014-2940", "type": "proceedings-article", "created": {"date-parts": [[2015, 5, 4]], "date-time": "2015-05-04T19:02:31Z", "timestamp": 1430766151000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 2940: Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody targeting tumor associated macrophages"], "prefix": "10.1158", "author": [{"given": "Ann-Marie", "family": "Br\u00f6ske", "sequence": "first", "affiliation": []}, {"given": "Irina", "family": "Klaman", "sequence": "additional", "affiliation": []}, {"given": "Jayantha", "family": "Ratnayake", "sequence": "additional", "affiliation": []}, {"given": "Georgina", "family": "Meneses-Lorente", "sequence": "additional", "affiliation": []}, {"given": "Kevin", "family": "Smart", "sequence": "additional", "affiliation": []}, {"given": "Phiippe", "family": "Cassier", "sequence": "additional", "affiliation": []}, {"given": "Carlos", "family": "Gomez-Roca", "sequence": "additional", "affiliation": []}, {"given": "Christophe L.", "family": "Tourneau", "sequence": "additional", "affiliation": []}, {"given": "Antoine", "family": "Italiano", "sequence": "additional", "affiliation": []}, {"given": "Jean-Pierre", "family": "Delord", "sequence": "additional", "affiliation": []}, {"given": "Jean-Yves", "family": "Blay", "sequence": "additional", "affiliation": []}, {"given": "Carola", "family": "Ries", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "Ruettinger", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Cannarile", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 9, 30]]}, "event": {"name": "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA"}, "container-title": ["Immunology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2014-2940", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T15:45:56Z", "timestamp": 1558194356000}, "score": 28.375921, "issued": {"date-parts": [[2014, 9, 30]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2014-2940"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2014-2940"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T20:16:58Z", "timestamp": 1575317818426}, "reference-count": 32, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2008, 11, 3]], "date-time": "2008-11-03T00:00:00Z", "timestamp": 1225670400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncogene"], "published-print": {"date-parts": [[2009, 1]]}, "DOI": "10.1038/onc.2008.394", "type": "journal-article", "created": {"date-parts": [[2008, 11, 3]], "date-time": "2008-11-03T11:09:05Z", "timestamp": 1225710545000}, "page": "461-468", "source": "Crossref", "is-referenced-by-count": 194, "title": ["Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab"], "prefix": "10.1038", "volume": "28", "author": [{"given": "M", "family": "Pickl", "sequence": "first", "affiliation": []}, {"given": "C H", "family": "Ries", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2008, 11, 3]]}, "reference": [{"key": "BFonc2008394_CR1", "doi-asserted-by": "publisher", "first-page": "20448", "DOI": "10.1074/jbc.273.32.20448", "volume": "273", "author": "JA Engelman", "year": "1998", "unstructured": "Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P et al. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273: 20448\u201320455.", "journal-title": "J Biol Chem"}, {"key": "BFonc2008394_CR2", "first-page": "140", "volume": "34", "author": "H Guo", "year": "2005", "unstructured": "Guo H, Wei B, Zhang HY, Liu GJ, Bu H, Lang ZQ et al. (2005). [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a meta-analysis]. Zhonghua Bing Li Xue Za Zhi 34: 140\u2013146.", "journal-title": "Zhonghua Bing Li Xue Za Zhi"}, {"key": "BFonc2008394_CR3", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.1056/NEJMra043186", "volume": "357", "author": "CA Hudis", "year": "2007", "unstructured": "Hudis CA . (2007). Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med 357: 39\u201351.", "journal-title": "N Engl J Med"}, {"key": "BFonc2008394_CR4", "doi-asserted-by": "publisher", "first-page": "1165", "DOI": "10.1128/MCB.9.3.1165", "volume": "9", "author": "RM Hudziak", "year": "1989", "unstructured": "Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A . (1989). p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165\u20131172.", "journal-title": "Mol Cell Biol"}, {"key": "BFonc2008394_CR5", "doi-asserted-by": "publisher", "first-page": "40025", "DOI": "10.1074/jbc.M509075200", "volume": "280", "author": "J-H Jung", "year": "2005", "unstructured": "Jung J-H, Traugh JA . (2005). Regulation of the interaction of Pak2 with Cdc42 via autophosphorylation of serine 141. J Biol Chem 280: 40025\u201340031.", "journal-title": "J Biol Chem"}, {"key": "BFonc2008394_CR6", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1074/jbc.275.1.423", "volume": "275", "author": "T Kwon", "year": "2000", "unstructured": "Kwon T, Kwon DY, Chun J, Kim JH, Kang SS . (2000). Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275: 423\u2013428.", "journal-title": "J Biol Chem"}, {"key": "BFonc2008394_CR7", "doi-asserted-by": "publisher", "first-page": "359", "DOI": "10.1038/nmeth1015", "volume": "4", "author": "GY Lee", "year": "2007", "unstructured": "Lee GY, Kenny PA, Lee EH, Bissell MJ . (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359\u2013365.", "journal-title": "Nat Methods"}, {"key": "BFonc2008394_CR8", "doi-asserted-by": "publisher", "first-page": "359", "DOI": "10.1002/ijc.21015", "volume": "116", "author": "KE Longva", "year": "2005", "unstructured": "Longva KE, Pedersen NM, Haslek\u00e5s C, Stang E, Madshus IH . (2005). Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116: 359\u2013367.", "journal-title": "Int J Cancer"}, {"key": "BFonc2008394_CR9", "first-page": "RE15", "volume": "2002", "author": "EA Miljan", "year": "2002", "unstructured": "Miljan EA, Bremer EG . (2002). Regulation of growth factor receptors by gangliosides. Sci STKE 2002: RE15.", "journal-title": "Sci STKE"}, {"key": "BFonc2008394_CR10", "doi-asserted-by": "publisher", "first-page": "201", "DOI": "10.1016/j.canlet.2005.01.028", "volume": "227", "author": "M-M Mocanu", "year": "2005", "unstructured": "Mocanu M-M, Fazekas Z, Petr\u00e1s M, Nagy P, Sebesty\u00e9n Z, Isola J et al. (2005). Associations of ErbB2, \u03b21-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 227: 201\u2013212.", "journal-title": "Cancer Lett"}, {"key": "BFonc2008394_CR11", "doi-asserted-by": "publisher", "first-page": "4251", "DOI": "10.1242/jcs.00118", "volume": "115", "author": "P Nagy", "year": "2002", "unstructured": "Nagy P, Vereb G, Sebesty\u00e9n Z, Horv\u00e1th G, Lockett SJ, Damjanovich S et al. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 115: 4251\u20134262.", "journal-title": "J Cell Sci"}, {"key": "BFonc2008394_CR12", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1016/j.canlet.2005.01.041", "volume": "232", "author": "R Nahta", "year": "2006", "unstructured": "Nahta R, Esteva FJ . (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123\u2013138.", "journal-title": "Cancer Lett"}, {"key": "BFonc2008394_CR13", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.3816/CBC.2004.n.011", "volume": "5", "author": "MA Owens", "year": "2004", "unstructured": "Owens MA, Horten BC, Da Silva MM . (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63\u201369.", "journal-title": "Clin Breast Cancer"}, {"key": "BFonc2008394_CR14", "doi-asserted-by": "publisher", "first-page": "9064", "DOI": "10.1073/pnas.89.19.9064", "volume": "89", "author": "OW Petersen", "year": "1992", "unstructured": "Petersen OW, R\u00f8nnov-Jessen L, Howlett AR, Bissell MJ . (1992). Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89: 9064\u20139068.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFonc2008394_CR15", "doi-asserted-by": "publisher", "first-page": "1597", "DOI": "10.1194/jlr.E600002-JLR200", "volume": "47", "author": "LJ Pike", "year": "2006", "unstructured": "Pike LJ . (2006). Rafts defined: a report on the Keystone symposium on lipid rafts and cell function. J Lipid Res 47: 1597\u20131598.", "journal-title": "J Lipid Res"}, {"key": "BFonc2008394_CR16", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.1042/bst0290494", "volume": "29", "author": "B Razani", "year": "2001", "unstructured": "Razani B, Schlegel A, Liu J, Lisanti MP . (2001). Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29: 494\u2013499.", "journal-title": "Biochem Soc Trans"}, {"key": "BFonc2008394_CR17", "doi-asserted-by": "publisher", "first-page": "4909", "DOI": "10.1158/1078-0432.CCR-07-0701", "volume": "13", "author": "CA Ritter", "year": "2007", "unstructured": "Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909\u20134919.", "journal-title": "Clin Cancer Res"}, {"key": "BFonc2008394_CR18", "doi-asserted-by": "publisher", "first-page": "274", "DOI": "10.1016/S0955-0674(99)80037-4", "volume": "11", "author": "SM Schoenwaelder", "year": "1999", "unstructured": "Schoenwaelder SM, Burridge K . (1999). Bidirectional signaling between the cytoskeleton and integrins. Curr Opin Cell Biol 11: 274\u2013286.", "journal-title": "Curr Opin Cell Biol"}, {"key": "BFonc2008394_CR19", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1007/s10911-004-1402-z", "volume": "9", "author": "KRM Shaw", "year": "2004", "unstructured": "Shaw KRM, Wrobel CN, Brugge JS . (2004). Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 9: 297\u2013310.", "journal-title": "J Mammary Gland Biol Neoplasia"}, {"key": "BFonc2008394_CR20", "doi-asserted-by": "publisher", "first-page": "4435", "DOI": "10.1073/pnas.72.11.4435", "volume": "72", "author": "S-I Shin", "year": "1975", "unstructured": "Shin S-I, Freedman VH, Risser R, Pollack R . (1975). Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435\u20134439.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFonc2008394_CR21", "doi-asserted-by": "publisher", "first-page": "707", "DOI": "10.1126/science.2470152", "volume": "244", "author": "DJ Slamon", "year": "1989", "unstructured": "Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707\u2013712.", "journal-title": "Science"}, {"key": "BFonc2008394_CR22", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1016/j.bbalip.2003.10.006", "volume": "1635", "author": "E Sottocornola", "year": "2003", "unstructured": "Sottocornola E, Berra B, Colombo I . (2003). GM3 content modulates the EGF-activated p185c-neu levels, but not those of the constitutively activated oncoprotein p185neu. Biochim Biophys Acta 1635: 55\u201366.", "journal-title": "Biochim Biophys Acta"}, {"key": "BFonc2008394_CR23", "doi-asserted-by": "publisher", "first-page": "1821", "DOI": "10.1111/j.1742-4658.2006.05203.x", "volume": "273", "author": "E Sottocornola", "year": "2006", "unstructured": "Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T et al. (2006). Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 273: 1821\u20131830.", "journal-title": "FEBS J"}, {"key": "BFonc2008394_CR24", "doi-asserted-by": "publisher", "first-page": "6573", "DOI": "10.1038/sj.onc.1205847", "volume": "21", "author": "JF Timms", "year": "2002", "unstructured": "Timms JF, White SL, O\u2019Hare MJ, Waterfield MD . (2002). Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21: 6573\u20136586.", "journal-title": "Oncogene"}, {"key": "BFonc2008394_CR25", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/S0093-7754(01)90289-1", "volume": "28", "author": "SC Wang", "year": "2001", "unstructured": "Wang SC, Hung MC . (2001). HER2 overexpression and cancer targeting. Semin Oncol 28: 115\u2013124.", "journal-title": "Semin Oncol"}, {"key": "BFonc2008394_CR26", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1016/S1535-6108(02)00125-3", "volume": "2", "author": "VM Weaver", "year": "2002", "unstructured": "Weaver VM, Leli\u00e8vre S, Lakins JN, Chrenek MA, Jones JCR, Giancotti F et al. (2002). \u03b24 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205\u2013216.", "journal-title": "Cancer Cell"}, {"key": "BFonc2008394_CR27", "doi-asserted-by": "publisher", "first-page": "118", "DOI": "10.1200/JCO.2006.09.2775", "volume": "25", "author": "AC Wolff", "year": "2007", "unstructured": "Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118\u2013145.", "journal-title": "J Clin Oncol"}, {"key": "BFonc2008394_CR28", "first-page": "4132", "volume": "62", "author": "FM Yakes", "year": "2002", "unstructured": "Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL . (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132\u20134141.", "journal-title": "Cancer Res"}, {"key": "BFonc2008394_CR29", "doi-asserted-by": "publisher", "first-page": "601", "DOI": "10.1016/j.cell.2007.08.006", "volume": "130", "author": "KM Yamada", "year": "2007", "unstructured": "Yamada KM, Cukierman E . (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601\u2013610.", "journal-title": "Cell"}, {"issue": "Suppl 4", "key": "BFonc2008394_CR30", "doi-asserted-by": "publisher", "first-page": "S3", "DOI": "10.1016/S0959-8049(01)00230-1", "volume": "37", "author": "Y Yarden", "year": "2001", "unstructured": "Yarden Y . (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3\u2013S8.", "journal-title": "Eur J Cancer"}, {"key": "BFonc2008394_CR31", "doi-asserted-by": "publisher", "first-page": "1972", "DOI": "10.1001/jama.291.16.1972", "volume": "291", "author": "H Yaziji", "year": "2004", "unstructured": "Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK et al. (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972\u20131977.", "journal-title": "JAMA"}, {"key": "BFonc2008394_CR32", "doi-asserted-by": "publisher", "first-page": "6779", "DOI": "10.1158/1078-0432.CCR-04-0112", "volume": "10", "author": "X Zhou", "year": "2004", "unstructured": "Zhou X, Tan M, Hawthorne VS, Klos KS, Lan KH, Yang Y et al. (2004). Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779\u20136788.", "journal-title": "Clin Cancer Res"}], "container-title": ["Oncogene"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/onc2008394.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/onc2008394", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/onc2008394.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T17:19:09Z", "timestamp": 1555694349000}, "score": 27.199268, "issued": {"date-parts": [[2008, 11, 3]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[2009, 1]]}, "issue": "3"}, "alternative-id": ["BFonc2008394"], "URL": "http://dx.doi.org/10.1038/onc.2008.394", "relation": {"cites": []}, "ISSN": ["0950-9232", "1476-5594"], "issn-type": [{"value": "0950-9232", "type": "print"}, {"value": "1476-5594", "type": "electronic"}], "subject": ["Genetics", "Cancer Research", "Molecular Biology"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:39:44Z", "timestamp": 1574113184573}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2000, 12, 1]], "date-time": "2000-12-01T00:00:00Z", "timestamp": 975628800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer Prostatic Dis"], "published-print": {"date-parts": [[2000, 12]]}, "DOI": "10.1038/sj.pcan.4500423", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T20:03:52Z", "timestamp": 1031169832000}, "page": "308-312", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Targeting of adenoviral vectors for gene therapy of prostate cancer"], "prefix": "10.1038", "volume": "3", "author": [{"given": "CH", "family": "Bangma", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2001, 1, 12]]}, "container-title": ["Prostate Cancer and Prostatic Diseases"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/4500423.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500423", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4500423.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 15]], "date-time": "2019-04-15T15:26:03Z", "timestamp": 1555341963000}, "score": 26.349884, "issued": {"date-parts": [[2000, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2000, 12]]}, "issue": "4"}, "alternative-id": ["BF4500423"], "URL": "http://dx.doi.org/10.1038/sj.pcan.4500423", "ISSN": ["1365-7852", "1476-5608"], "issn-type": [{"value": "1365-7852", "type": "print"}, {"value": "1476-5608", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T10:08:06Z", "timestamp": 1574590086354}, "reference-count": 1, "publisher": "Oxford University Press (OUP)", "issue": "suppl 2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Annals of Oncology"], "published-print": {"date-parts": [[2015, 3, 1]]}, "DOI": "10.1093/annonc/mdv086.3", "type": "journal-article", "created": {"date-parts": [[2015, 3, 20]], "date-time": "2015-03-20T17:00:46Z", "timestamp": 1426870846000}, "page": "ii12-ii12", "source": "Crossref", "is-referenced-by-count": 0, "title": ["O8.3 * Targeting tumor-associated macrophages in cancer patients"], "prefix": "10.1093", "volume": "26", "author": [{"given": "D.", "family": "Ruttinger", "sequence": "first", "affiliation": []}, {"given": "P.", "family": "Cassier", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Cannarile", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Ries", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Gomez-Roca", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "D'Angelo", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Weber", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Campone", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Le Tourneau", "sequence": "additional", "affiliation": []}, {"given": "J.- P.", "family": "Delord", "sequence": "additional", "affiliation": []}, {"given": "J.- Y.", "family": "Blay", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Italiano", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2015, 3, 20]]}, "reference": [{"key": "2_49199774", "ISSN": "http://id.crossref.org/issn/1535-6108", "issn-type": "print", "volume": "25", "first-page": "846", "year": "2014", "journal-title": "Cancer cell", "DOI": "10.1016/j.ccr.2014.05.016", "doi-asserted-by": "crossref"}], "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/26/suppl_2/ii12/6675286/mdv086.3.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 22]], "date-time": "2017-08-22T18:03:17Z", "timestamp": 1503424997000}, "score": 25.561253, "issued": {"date-parts": [[2015, 3, 1]]}, "references-count": 1, "journal-issue": {"published-online": {"date-parts": [[2015, 3, 20]]}, "published-print": {"date-parts": [[2015, 3, 1]]}, "issue": "suppl 2"}, "URL": "http://dx.doi.org/10.1093/annonc/mdv086.3", "relation": {"cites": []}, "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:27:42Z", "timestamp": 1575530862510}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "7", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1995, 10, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>A fusion protein was synthesized consisting of the murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) gene spliced to a truncated form of the diphtheria toxin (DT390) gene coding for a molecule that retained full enzymatic activity, but excluded the native binding domain. The DT390-mGM-CSF hybrid gene was cloned into a vector under the control of an inducible promoter and the protein expressed in Escherichia coli. After induction, a protein was purified from inclusion bodies in accord with the deduced molecular weight of DT390 mGM-CSF. Cell-free studies of the adenosine diphosphate-ribosylating activity of DT390 mGM-CSF showed results that were similar to those of native DT. The DT390 mGM-CSF immunotoxin inhibited FDCP2.1d, a murine myelomonocytic tumor line expressing the GM-CSF receptor with an IC50 (concentration inhibiting 50% activity) of 5 x 10(-11) mol/L. The fusion toxin was specifically cytotoxic and directed by the GM-CSF portion of the molecule because addition of a monoclonal antibody directed against GM-CSF inhibited its ability to kill the cell line. Cell lines that do not express GM-CSF receptor were not inhibited by the fusion toxin. DT390 mGM-CSF was also able to specifically inhibit normal committed bone marrow (BM) progenitor cells as measured in clonal colony-forming unit granulocyte-macrophage assays. Together, these findings indicate that DT390 mGM-CSF may be useful as a novel tool for purging BM of contaminating leukemia cells or in vivo for eliminating residual leukemia cells. Also, it can be used to determine whether committed and/or noncommitted BM progenitor cells express the GM-CSF receptor.</jats:p>", "DOI": "10.1182/blood.v86.7.2732.2732", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T02:17:21Z", "timestamp": 1571019441000}, "page": "2732-2740", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 8, "title": ["A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells"], "prefix": "10.1182", "volume": "86", "author": [{"given": "CH", "family": "Chan", "sequence": "first", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "BR", "family": "Blazar", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "CR", "family": "Eide", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "RJ", "family": "Kreitman", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "DA", "family": "Vallera", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/86/7/2732/622284/2732.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/86/7/2732/622284/2732.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:40:19Z", "timestamp": 1574246419000}, "score": 24.396446, "issued": {"date-parts": [[1995, 10, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1995, 10, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1182/blood.v86.7.2732.2732", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:21:30Z", "timestamp": 1575530490898}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "7", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[1995, 10, 1]]}, "abstract": "<jats:p>A fusion protein was synthesized consisting of the murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) gene spliced to a truncated form of the diphtheria toxin (DT390) gene coding for a molecule that retained full enzymatic activity, but excluded the native binding domain. The DT390-mGM-CSF hybrid gene was cloned into a vector under the control of an inducible promoter and the protein expressed in Escherichia coli. After induction, a protein was purified from inclusion bodies in accord with the deduced molecular weight of DT390 mGM-CSF. Cell-free studies of the adenosine diphosphate-ribosylating activity of DT390 mGM-CSF showed results that were similar to those of native DT. The DT390 mGM-CSF immunotoxin inhibited FDCP2.1d, a murine myelomonocytic tumor line expressing the GM-CSF receptor with an IC50 (concentration inhibiting 50% activity) of 5 x 10(-11) mol/L. The fusion toxin was specifically cytotoxic and directed by the GM-CSF portion of the molecule because addition of a monoclonal antibody directed against GM-CSF inhibited its ability to kill the cell line. Cell lines that do not express GM-CSF receptor were not inhibited by the fusion toxin. DT390 mGM-CSF was also able to specifically inhibit normal committed bone marrow (BM) progenitor cells as measured in clonal colony-forming unit granulocyte-macrophage assays. Together, these findings indicate that DT390 mGM-CSF may be useful as a novel tool for purging BM of contaminating leukemia cells or in vivo for eliminating residual leukemia cells. Also, it can be used to determine whether committed and/or noncommitted BM progenitor cells express the GM-CSF receptor.</jats:p>", "DOI": "10.1182/blood.v86.7.2732.bloodjournal8672732", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T13:12:28Z", "timestamp": 1570972348000}, "page": "2732-2740", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells"], "prefix": "10.1182", "volume": "86", "author": [{"given": "CH", "family": "Chan", "sequence": "first", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "BR", "family": "Blazar", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "CR", "family": "Eide", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "RJ", "family": "Kreitman", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}, {"given": "DA", "family": "Vallera", "sequence": "additional", "affiliation": [{"name": "Department of Therapeutic Radiology, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA."}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/86/7/2732/233542/2732.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/86/7/2732/233542/2732.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:49:54Z", "timestamp": 1574243394000}, "score": 24.396446, "issued": {"date-parts": [[1995, 10, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1995, 10, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1182/blood.v86.7.2732.bloodjournal8672732", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T05:43:55Z", "timestamp": 1574315035679}, "publisher-location": "Berlin, Heidelberg", "reference-count": 36, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540439783", "type": "print"}, {"value": "9783540456469", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002]]}, "DOI": "10.1007/3-540-45646-5_12", "type": "book-chapter", "created": {"date-parts": [[2007, 8, 7]], "date-time": "2007-08-07T04:42:01Z", "timestamp": 1186461721000}, "page": "233-251", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Targeted Tumor Therapy with \u201cMagnetic Drug Targeting\u201d: Therapeutic Efficacy of Ferrofluid Bound Mitoxantrone"], "prefix": "10.1007", "author": [{"given": "Ch.", "family": "Alexiou", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Schmid", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Jurgons", "sequence": "additional", "affiliation": []}, {"given": "Ch.", "family": "Bergemann", "sequence": "additional", "affiliation": []}, {"given": "W.", "family": "Arnold", "sequence": "additional", "affiliation": []}, {"given": "F. G.", "family": "Parak", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2002, 11, 6]]}, "reference": [{"key": "12_CR1", "first-page": "212", "volume": "60", "author": "J.F. Alksne", "year": "1966", "unstructured": "Alksne JF, Fingerhut A, Rand R. Magnetically controlled metallic thrombosis of intracranial aneurysms. Surgery 1966; 60: 212\u2013218.", "journal-title": "Surgery"}, {"key": "12_CR2", "doi-asserted-by": "crossref", "first-page": "529", "DOI": "10.1148/113.3.529", "volume": "113", "author": "S.K. Hilal", "year": "1974", "unstructured": "Hilal SK, Michelsen WJ, Driller J, Leonard E. Magnetically guided devices for vascular exploration and treatment. Radiology 1974;113: 529\u2013534.", "journal-title": "Radiology"}, {"key": "12_CR3", "doi-asserted-by": "publisher", "first-page": "317", "DOI": "10.1002/ccd.1810220412", "volume": "22", "author": "W. Ram", "year": "1991", "unstructured": "Ram, W. and Meyer, H. Heart catheterization in a neonate by interacting magnetic fields. A new and simple method of catheterguidance. Catheterization and Cardiovascular Diagnosis, 22: 317\u2013319, 1991.", "journal-title": "Catheterization and Cardiovascular Diagnosis"}, {"key": "12_CR4", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.1109/10.398640", "volume": "42", "author": "R. G. McNeil", "year": "1995", "unstructured": "McNeil, R. G., Ritter, R. C., Wang, B. et al. Functional design features and initial performance characteristics of a magnetic-implant guidance system for stereotactic neurosurgery. IEEE Transactions on Biomedical Engineering, 42: 793\u2013801, 1995.", "journal-title": "IEEE Transactions on Biomedical Engineering"}, {"key": "12_CR5", "unstructured": "Luborsky, F.E. Recent advances in the removal of magnetic foreign bodies from the esophagus, stomach and duodenum with controllable permanent magnets. Am. J. Roentg. Rad. Ther. Nucl. Med., 1964."}, {"key": "12_CR6", "doi-asserted-by": "crossref", "first-page": "723", "DOI": "10.2214/ajr.149.4.723", "volume": "149", "author": "R. Weissleder", "year": "1987", "unstructured": "Weissleder R, Hahn PF, Stark DD et al. MR imaging of splenic metastases: ferrite-enhanced detection in rats. AJR 1987; 149: 723\u2013726.", "journal-title": "AJR"}, {"key": "12_CR7", "doi-asserted-by": "crossref", "first-page": "167", "DOI": "10.2214/ajr.152.1.167", "volume": "152", "author": "R. Weissleder", "year": "1989", "unstructured": "Weissleder R, Stark DD, Engelstad BL et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989;152: 167\u2013173.", "journal-title": "AJR"}, {"key": "12_CR8", "doi-asserted-by": "crossref", "first-page": "494", "DOI": "10.1148/radiology.175.2.2326475", "volume": "175", "author": "R. Weissleder", "year": "1990", "unstructured": "Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultra-small superparamagnetic iron oxide. An intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990;175: 494.", "journal-title": "Radiology"}, {"key": "12_CR9", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1177/028418519303400103", "volume": "34", "author": "M. Taupitz", "year": "1993", "unstructured": "Taupitz M, Wagner S, Hamm B, Dienemann D, Lawaczeck R, Wolf KJ. MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumor model. Acta Radiol. 1993; 34: 10\u201315.", "journal-title": "Acta Radiol"}, {"key": "12_CR10", "unstructured": "Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH. Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Molec. Med. 195;1: 789\u2013794.", "DOI": "10.1007/BF03401893", "doi-asserted-by": "crossref"}, {"issue": "5", "key": "12_CR11", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1111/j.1525-1594.1992.tb00329.x", "volume": "16", "author": "Y. Mitamura", "year": "1992", "unstructured": "Mitamura Y, Wada T, Keisuke S. A ferrofluidic actuator for an implantable artificial heart. Artif. Organs 1992; 16(5): 490\u2013495.", "journal-title": "Artif. Organs"}, {"key": "12_CR12", "first-page": "6641", "volume": "60", "author": "C. Alexiou", "year": "2000", "unstructured": "Alexiou, C., Arnold, W., Klein, R.J. et al. Locoregional cancer treatment with Magnetic Drug Targeting. Cancer Res 2000; 60: 6641\u20136648.", "journal-title": "Cancer Res"}, {"key": "12_CR13", "doi-asserted-by": "crossref", "first-page": "187", "DOI": "10.1016/S0304-8853(00)01256-7", "volume": "255", "author": "C. Alexiou", "year": "2001", "unstructured": "Alexiou, C., Arnold, W., Hulin, P. et al. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. JMMM 2001;255: 187\u2013193.", "journal-title": "JMMM"}, {"key": "12_CR14", "unstructured": "Alexiou, C., Schmidt, A., Klein, R.J. et al. Magnetic drug targeting: Biodistribution and dependency on magnetic field strength. JMMM in press.", "DOI": "10.1016/S0304-8853(02)00605-4", "doi-asserted-by": "crossref"}, {"key": "12_CR15", "first-page": "4694", "volume": "56", "author": "A.S. L\u00fcbbe", "year": "1996", "unstructured": "L\u00fcbbe AS, Bergemann C, Huhnt W et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 1996; 56: 4694\u20134701.", "journal-title": "Cancer Res"}, {"key": "12_CR16", "first-page": "14", "volume": "17", "author": "A. D. Ho", "year": "1990", "unstructured": "Ho, A. D., Del Valle, F., Haas, R. et al. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin\u2019s lymphoma. Semin. Oncol., 17: 14\u201318, 1990.", "journal-title": "Semin. Oncol."}, {"key": "12_CR17", "first-page": "637", "volume": "4", "author": "W. Hiddemann", "year": "1990", "unstructured": "Hiddemann, W., Buchner, T., Heil, G. et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia., 4:637\u2013640, 1990.", "journal-title": "Leukemia"}, {"key": "12_CR18", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1007/BF01715350", "volume": "64", "author": "M. Freund", "year": "1992", "unstructured": "Freund, M., Wunsch-Zeddies, S., Schafers, M. et al. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin\u2019s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). Ann. Hematol., 64: 83\u201387, 1992.", "journal-title": "Ann. Hematol."}, {"key": "12_CR19", "first-page": "907", "year": "1995", "unstructured": "Bistner SI, Ford RB, Raffe MR (eds.). Kirk and Bistner\u2019s Handbook of Veterinarian Procedures and Emergency Treatment, Ed 6, p. 907. Philadelphia: W.B. Saunders Co., 1995.", "volume-title": "Kirk and Bistner\u2019s Handbook of Veterinarian Procedures and Emergency Treatment"}, {"key": "12_CR20", "first-page": "4", "volume": "1", "author": "F. O. Stephens", "year": "1988", "unstructured": "Stephens, F. O. Why use regional chemotherapy? Principles and pharmacokinetics. Reg Cancer Treat., 1: 4\u201310, 1988.", "journal-title": "Reg Cancer Treat."}, {"key": "12_CR21", "doi-asserted-by": "publisher", "first-page": "344", "DOI": "10.1007/s004230050212", "volume": "384", "author": "K.H. Link", "year": "1999", "unstructured": "Link, K.H., Kornmann, M., Formenti, A. et al. Regional chemotherapy of nonresectable liver metastases from colorectal cancer \u2014 literature and institutional review. Langenbecks Arch. Surg., 384: 344\u2013353, 1999.", "journal-title": "Langenbecks Arch. Surg."}, {"key": "12_CR22", "author": "J. Scheel v.", "year": "1998", "unstructured": "v. Scheel, J.: Invasive procedures for antineoplastic chemotherapy. In: Naumann et al. (eds.): Head and Neck Surgery. Stuttgart, New York: Thieme, 1998.", "volume-title": "Head and Neck Surgery"}, {"key": "12_CR23", "doi-asserted-by": "publisher", "first-page": "288", "DOI": "10.1016/0026-2862(86)90018-X", "volume": "31", "author": "L.E. Gerlowski", "year": "1986", "unstructured": "Gerlowski, L.E. and Jain, R.K. Microvascular permeability of normal and neoplastic tissues. Microvascular Research 31: 288\u2013305, 1986.", "journal-title": "Microvascular Research"}, {"key": "12_CR24", "doi-asserted-by": "publisher", "first-page": "1397", "DOI": "10.1002/1097-0142(19840315)53:6<1397::AID-CNCR2820530630>3.0.CO;2-E", "volume": "53", "author": "A.J. Swistel", "year": "1984", "unstructured": "Swistel AJ, Bading JR and Raaf JH Intraarterial versus intravenous Adriamycin in the VX2 tumor system. Cancer (Phila.) 53: 1397\u20131404, 1984", "journal-title": "Cancer"}, {"key": "12_CR25", "doi-asserted-by": "publisher", "first-page": "3578", "DOI": "10.1063/1.325219", "volume": "49", "author": "A. Senyei", "year": "1978", "unstructured": "Senyei, A., Widder, K., and Czerlinski, C. Magnetic guidance of drug carrying microspheres. J. Appl. Physiol., 49: 3578\u20133583, 1978.", "journal-title": "J. Appl. Physiol."}, {"key": "12_CR26", "doi-asserted-by": "publisher", "first-page": "132", "DOI": "10.1016/S0304-8853(98)00584-8", "volume": "194", "author": "S. Goodwin", "year": "1999", "unstructured": "Goodwin, S., Peterson, C., Hoh, C., Bittner, C. Targeting and retention of magnetic targeted carriers. J. Magn. Magn. Mater., 194: 132\u2013139, 1999.", "journal-title": "J. Magn. Magn. Mater."}, {"key": "12_CR27", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1016/S0304-8853(98)00554-X", "volume": "194", "author": "C. Bergemann", "year": "1999", "unstructured": "Bergemann, C., M\u00fcller-Schulte, D., Oster, J., \u00e0 Brassard, L., L\u00fcbbe, A.S. Magnetic ionexchange nano-and microparticles for medical, biomedical and molecular biological applications. J. Magn. Magn. Mater.,194: 45\u201352, 1999.", "journal-title": "J. Magn. Magn. Mater."}, {"key": "12_CR28", "first-page": "4694", "volume": "56", "author": "A. S. L\u00fcbbe", "year": "1996", "unstructured": "L\u00fcbbe, A. S., Bergemann, Ch., Huhnt, W., Fricke, T., Riess, H., Brock, J. W., and Huhn, D. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Research, 56: 4694\u20134701, 1996.", "journal-title": "Cancer Research"}, {"key": "12_CR29", "first-page": "4686", "volume": "56", "author": "A. S. L\u00fcbbe", "year": "1996", "unstructured": "L\u00fcbbe, A. S., Bergemann, Ch., Riess, H. et al. Clinical experiences with magnetic drug targeting: a phase I study with 4\u2019-epidoxorubicin in 14 patients with advanced solid tumors. Cancer research, 56: 4686\u20134693, 1996.", "journal-title": "Cancer research"}, {"key": "12_CR30", "doi-asserted-by": "publisher", "first-page": "10", "DOI": "10.3109/02841859309173228", "volume": "34", "author": "M. Taupitz", "year": "1993", "unstructured": "Taupitz, M., Wagner, S., Hamm, B., Dienemann, D., Lawaczeck, R. and Wolf, K.J. MR Lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumor model. Acta Radiologica, 34:10\u201315, 1993.", "journal-title": "Acta Radiologica"}, {"key": "12_CR31", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.3181/00379727-158-40158", "volume": "58", "author": "K.J. Widder", "year": "1978", "unstructured": "Widder, K.J., Senyei, A.E. and Scarpelli, D.G. Magnetic microspheres: a model system for site specific drug deleivery in vivo. Proc. Soc. Exp. Biol. Med. 58: 141\u2013146, 1978.", "journal-title": "Proc. Soc. Exp. Biol. Med."}, {"key": "12_CR32", "first-page": "164", "volume": "110", "author": "B.R. Bacon", "year": "1987", "unstructured": "Bacon, B.R., Park, D. D., Saini, S., Groman, E. V., Hahn, P. F., Compton, C. C., and Ferrucci, J. T. Ferrite particles: A new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatoxicity after intravenous administration. J. Lab. Clin. Med., 110: 164\u2013171, 1987.", "journal-title": "J. Lab. Clin. Med."}, {"key": "12_CR33", "first-page": "380", "volume": "28", "author": "E. Rummeny", "year": "1988", "unstructured": "Rummeny, E., Weissleder, R., Stark, D. D., Elizondo, G. and Ferrucci, J. T. Magnetic resonance tomography of focal liver and spleen lesions. Experiences using ferrite, a new RES-specific MR contrast medium. Radiologe 28: 380\u2013386, 1988.", "journal-title": "Radiologe"}, {"key": "12_CR34", "author": "U.O. H\u00e4feli", "first-page": "501", "year": "1997", "unstructured": "H\u00e4feli, U.O., Pauer, G.J., Roberts, W.K., Humm, J.L. and Macklis, R.M. Magnetically targeted microspheres for intracavitary and intraspinal Y-90 radiotharpy. In: U. H\u00e4feli and W. Sch\u00fctt (eds.), Scientific and clinical applications of magnetic carriers, pp 501\u2013516, New York and London: Plenum press, 1997.", "volume-title": "Scientific and clinical applications of magnetic carriers", "DOI": "10.1007/978-1-4757-6482-6_38", "doi-asserted-by": "crossref"}, {"key": "12_CR35", "doi-asserted-by": "publisher", "first-page": "587", "DOI": "10.3109/02656739709023559", "volume": "13", "author": "A. Jordan", "year": "1997", "unstructured": "Jordan, A., Scholz, R., Wust, P. et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int. J. Hyperthermia, 13: 587\u2013605, 1997.", "journal-title": "Int. J. Hyperthermia"}, {"key": "12_CR36", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1002/(SICI)1096-9896(199911)189:3<368::AID-PATH441>3.0.CO;2-2", "volume": "189", "author": "M. Partridge", "year": "1999", "unstructured": "Partridge, M., Phillips, E., Francis, R., Li, S.R. Immunomagnetic seperation for enrichment and sensitive detection of disseminated tumour cells in patients with head and neck SCC. J. Pathol., 189: 368\u2013377, 1999.", "journal-title": "J. Pathol."}], "container-title": ["Ferrofluids", "Lecture Notes in Physics"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/3-540-45646-5_12", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 1]], "date-time": "2019-05-01T20:03:39Z", "timestamp": 1556741019000}, "score": 23.160942, "issued": {"date-parts": [[2002]]}, "ISBN": ["9783540439783", "9783540456469"], "references-count": 36, "URL": "http://dx.doi.org/10.1007/3-540-45646-5_12", "relation": {"cites": []}, "ISSN": ["0075-8450"], "issn-type": [{"value": "0075-8450", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:29:57Z", "timestamp": 1574486997659}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2009, 1, 15]]}, "DOI": "10.1158/0008-5472.sabcs-2136", "type": "proceedings-article", "created": {"date-parts": [[2010, 12, 30]], "date-time": "2010-12-30T23:31:29Z", "timestamp": 1293751889000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer."], "prefix": "10.1158", "author": [{"given": "PD", "family": "Ryan", "sequence": "first", "affiliation": []}, {"given": "P", "family": "Neven", "sequence": "additional", "affiliation": []}, {"given": "LY", "family": "Dirix", "sequence": "additional", "affiliation": []}, {"given": "CH", "family": "Barrios", "sequence": "additional", "affiliation": []}, {"given": "WH", "family": "Miller", "sequence": "additional", "affiliation": []}, {"given": "D", "family": "Fenton", "sequence": "additional", "affiliation": []}, {"given": "MF", "family": "Abraham", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Paccagnella", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Gualberto", "sequence": "additional", "affiliation": []}, {"given": "PE", "family": "Goss", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 7]]}, "event": {"name": "CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts"}, "container-title": ["Poster Session Abstracts"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.SABCS-2136", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T22:19:39Z", "timestamp": 1558217979000}, "score": 23.063019, "issued": {"date-parts": [[2009, 1, 15]]}, "references-count": 0, "alternative-id": ["10.1158/0008-5472.SABCS-2136"], "URL": "http://dx.doi.org/10.1158/0008-5472.sabcs-2136"}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T14:26:19Z", "timestamp": 1575383179692}, "reference-count": 0, "publisher": "S. Karger AG", "isbn-type": [{"value": "9783805546478", "type": "print"}, {"value": "9783318034097", "type": "electronic"}], "license": [{"URL": "https://www.karger.com/Services/SiteLicenses", "start": {"date-parts": [[1987, 1, 1]], "date-time": "1987-01-01T00:00:00Z", "timestamp": 536457600000}, "delay-in-days": 0, "content-version": "vor"}, {"URL": "https://www.karger.com/Services/SiteLicenses", "start": {"date-parts": [[1987, 1, 1]], "date-time": "1987-01-01T00:00:00Z", "timestamp": 536457600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1987]]}, "DOI": "10.1159/000429528", "type": "book-chapter", "created": {"date-parts": [[2019, 1, 15]], "date-time": "2019-01-15T13:11:22Z", "timestamp": 1547557882000}, "page": "93-104", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Pharmacological and Toxicological Effects of Ifosfamide (Holoxan\u00ae) Combined with Mesna (Uromitexan\u00ae) in Different Murine Tumor Models"], "prefix": "10.1159", "author": [{"given": "I.", "family": "Fichtner", "sequence": "first", "affiliation": []}, {"given": "Ch.", "family": "Nowak", "sequence": "additional", "affiliation": []}], "member": "127", "published-online": {"date-parts": [[2015, 4, 5]]}, "container-title": ["Contributions to Oncology", "Ifosfamide in Tumor Therapy"], "link": [{"URL": "https://www.karger.com/Article/Pdf/429528", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 15]], "date-time": "2019-01-15T13:11:22Z", "timestamp": 1547557882000}, "score": 22.84259, "issued": {"date-parts": [[1987]]}, "ISBN": ["9783805546478", "9783318034097"], "references-count": 0, "URL": "http://dx.doi.org/10.1159/000429528", "ISSN": ["0250-3220", "1662-2928"], "issn-type": [{"value": "0250-3220", "type": "print"}, {"value": "1662-2928", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T14:27:05Z", "timestamp": 1574519225434}, "publisher-location": "London", "reference-count": 25, "publisher": "Springer London", "isbn-type": [{"value": "9780857297860", "type": "print"}, {"value": "9780857297877", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013]]}, "DOI": "10.1007/978-0-85729-787-7_14", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 1]], "date-time": "2012-12-01T14:26:13Z", "timestamp": 1354371973000}, "page": "465-481", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Preservation of Fertility in the Cancer Patient"], "prefix": "10.1007", "author": [{"given": "Duhem", "family": "Caroline", "sequence": "first", "affiliation": []}, {"given": "Fernand", "family": "Ries", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 10, 31]]}, "reference": [{"issue": "5", "key": "14_CR00141", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1016/S1470-2045(09)70317-1", "volume": "11", "author": "JM Knopman", "year": "2010", "unstructured": "Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11(5):490\u20138.", "journal-title": "Lancet Oncol"}, {"issue": "32", "key": "14_CR00142", "doi-asserted-by": "publisher", "first-page": "4831", "DOI": "10.1200/JCO.2009.22.8312", "volume": "28", "author": "J Levine", "year": "2010", "unstructured": "Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831\u201341.", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "14_CR00143", "doi-asserted-by": "publisher", "first-page": "422", "DOI": "10.1634/theoncologist.11-5-422", "volume": "11", "author": "M Sonmezer", "year": "2006", "unstructured": "Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11(5):422\u201334.", "journal-title": "Oncologist"}, {"issue": "9", "key": "14_CR00144", "doi-asserted-by": "publisher", "first-page": "902", "DOI": "10.1056/NEJMra0801454", "volume": "360", "author": "JS Jeruss", "year": "2009", "unstructured": "Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902\u201311.", "journal-title": "N Engl J Med"}, {"issue": "13", "key": "14_CR00145", "doi-asserted-by": "publisher", "first-page": "1670", "DOI": "10.1200/JCO.2010.31.2462", "volume": "29", "author": "M Peate", "year": "2011", "unstructured": "Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It\u2019s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer \u2013 an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "14_CR00146", "doi-asserted-by": "publisher", "first-page": "1017", "DOI": "10.1016/j.fertnstert.2005.05.015", "volume": "84", "author": "J Feldschuh", "year": "2005", "unstructured": "Feldschuh J, Brassel J, Durso N, Levine A. Successful sperm storage for 28 years. Fertil Steril. 2005;84(4):1017.", "journal-title": "Fertil Steril"}, {"issue": "13", "key": "14_CR00147", "doi-asserted-by": "publisher", "first-page": "3102", "DOI": "10.1002/cncr.25106", "volume": "116", "author": "P Sukumvanich", "year": "2010", "unstructured": "Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102\u201311.", "journal-title": "Cancer"}, {"issue": "5", "key": "14_CR00148", "doi-asserted-by": "publisher", "first-page": "1635", "DOI": "10.1016/j.fertnstert.2007.09.048", "volume": "90", "author": "A Reh", "year": "2008", "unstructured": "Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635\u20139.", "journal-title": "Fertil Steril"}, {"issue": "6", "key": "14_CR00149", "doi-asserted-by": "publisher", "first-page": "2125.e9", "DOI": "10.1016/j.fertnstert.2011.01.030", "volume": "95", "author": "M S\u00f6nmezer", "year": "2011", "unstructured": "S\u00f6nmezer M, T\u00fcrk\u00e7\u00fco\u011flu I, Co\u015fkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125.e9\u201311.", "journal-title": "Fertil Steril"}, {"issue": "19", "key": "14_CR001410", "doi-asserted-by": "publisher", "first-page": "4347", "DOI": "10.1200/JCO.2005.05.037", "volume": "23", "author": "K Oktay", "year": "2005", "unstructured": "Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347\u201353.", "journal-title": "J Clin Oncol"}, {"issue": "16", "key": "14_CR001411", "doi-asserted-by": "publisher", "first-page": "2630", "DOI": "10.1200/JCO.2007.14.8700", "volume": "26", "author": "AA Azim", "year": "2008", "unstructured": "Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630\u20135.", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "14_CR001412", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1016/j.bpobgyn.2009.09.002", "volume": "24", "author": "M Sonmezer", "year": "2010", "unstructured": "Sonmezer M, Oktay K. Orthotopic and heterotopic ovarian tissue transplantation. Best Pract Res Clin Obstet Gynaecol. 2010;24(1):113\u201326.", "journal-title": "Best Pract Res Clin Obstet Gynaecol"}, {"issue": "9443", "key": "14_CR001413", "doi-asserted-by": "publisher", "first-page": "1405", "DOI": "10.1016/S0140-6736(04)17222-X", "volume": "364", "author": "J Donnez", "year": "2004", "unstructured": "Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405\u201310. Erratum in: Lancet. 2004;364(9450):2020.", "journal-title": "Lancet"}, {"issue": "16", "key": "14_CR001414", "doi-asserted-by": "publisher", "first-page": "2908", "DOI": "10.1182/blood-2010-01-265751", "volume": "116", "author": "MM Dolmans", "year": "2010", "unstructured": "Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908\u201314.", "journal-title": "Blood"}, {"issue": "6", "key": "14_CR001415", "doi-asserted-by": "publisher", "first-page": "2158", "DOI": "10.1016/j.fertnstert.2010.12.019", "volume": "95", "author": "M Rosendahl", "year": "2011", "unstructured": "Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in \u00adovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158\u201361.", "journal-title": "Fertil Steril"}, {"issue": "17", "key": "14_CR001416", "doi-asserted-by": "publisher", "first-page": "2334", "DOI": "10.1200/JCO.2010.32.5704", "volume": "29", "author": "B Gerber", "year": "2011", "unstructured": "Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334\u201341.", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "14_CR001417", "doi-asserted-by": "publisher", "first-page": "269", "DOI": "10.1001/jama.2011.991", "volume": "306", "author": "L Mastro Del", "year": "2011", "unstructured": "Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269\u201376.", "journal-title": "JAMA"}, {"issue": "3", "key": "14_CR001418", "doi-asserted-by": "publisher", "first-page": "906", "DOI": "10.1016/j.fertnstert.2010.11.017", "volume": "95", "author": "MA Bedaiwy", "year": "2011", "unstructured": "Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906\u201314.e1\u20134.", "journal-title": "Fertil Steril"}, {"issue": "10", "key": "14_CR001419", "doi-asserted-by": "publisher", "first-page": "2052", "DOI": "10.1093/annonc/mdq066", "volume": "21", "author": "K Behringer", "year": "2010", "unstructured": "Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052\u201360.", "journal-title": "Ann Oncol"}, {"issue": "18", "key": "14_CR001420", "doi-asserted-by": "publisher", "first-page": "2917", "DOI": "10.1200/JCO.2006.06.5888", "volume": "24", "author": "SJ Lee", "year": "2006", "unstructured": "Lee SJ, Schover LR, Partridge AH, Patrizio P, Hamish Wallace W, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917\u201331.", "journal-title": "J Clin Oncol"}, {"issue": "35", "key": "14_CR001421", "doi-asserted-by": "publisher", "first-page": "5952", "DOI": "10.1200/JCO.2009.23.0250", "volume": "27", "author": "GP Quinn", "year": "2009", "unstructured": "Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "14_CR001422", "doi-asserted-by": "publisher", "first-page": "1890", "DOI": "10.1200/JCO.2002.07.174", "volume": "20", "author": "LR Schover", "year": "2002", "unstructured": "Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists\u2019 attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol. 2002;20(7):1890\u20137.", "journal-title": "J Clin Oncol"}, {"key": "14_CR001423", "unstructured": "Quinn GP, Vadaparampil ST, Malo T, Reinecke J, Bower B, Albrecht T, et al. Oncologists\u2019 use of patient educational materials about cancer and fertility preservation. Psychooncology. 2011. doi:\n                10.1002/pon.2022\n                \n              .", "DOI": "10.1002/pon.2022", "doi-asserted-by": "publisher"}, {"key": "14_CR001424", "unstructured": "Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2011. doi:\n                10.1002/cncr.26459\n                \n              .", "DOI": "10.1002/cncr.26459", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "14_CR001425", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1016/j.ejca.2010.09.007", "volume": "47", "author": "HA Azim Jr", "year": "2011", "unstructured": "Azim Jr HA, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74\u201383.", "journal-title": "Eur J Cancer"}], "container-title": ["Side Effects of Medical Cancer Therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-0-85729-787-7_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T13:10:20Z", "timestamp": 1557407420000}, "score": 22.807629, "issued": {"date-parts": [[2012, 10, 31]]}, "ISBN": ["9780857297860", "9780857297877"], "references-count": 25, "URL": "http://dx.doi.org/10.1007/978-0-85729-787-7_14", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T22:39:44Z", "timestamp": 1575326384138}, "publisher-location": "Cham", "reference-count": 34, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319702520", "type": "print"}, {"value": "9783319702537", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 1, 1]], "date-time": "2018-01-01T00:00:00Z", "timestamp": 1514764800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018]]}, "DOI": "10.1007/978-3-319-70253-7_13", "type": "book-chapter", "created": {"date-parts": [[2018, 6, 27]], "date-time": "2018-06-27T15:05:42Z", "timestamp": 1530111942000}, "page": "355-366", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Preservation of Fertility in the Cancer Patient"], "prefix": "10.1007", "author": [{"given": "Duhem", "family": "Caroline", "sequence": "first", "affiliation": []}, {"given": "Fernand", "family": "Ries", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 6, 28]]}, "reference": [{"issue": "5", "key": "13_CR1", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1016/S1470-2045(09)70317-1", "volume": "11", "author": "JM Knopman", "year": "2010", "unstructured": "Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11(5):490\u20138.", "journal-title": "Lancet Oncol"}, {"issue": "32", "key": "13_CR2", "doi-asserted-by": "publisher", "first-page": "4831", "DOI": "10.1200/JCO.2009.22.8312", "volume": "28", "author": "J Levine", "year": "2010", "unstructured": "Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831\u201341.", "journal-title": "J Clin Oncol"}, {"issue": "15", "key": "13_CR3", "doi-asserted-by": "publisher", "first-page": "1780", "DOI": "10.1200/JCO.2015.64.5168", "volume": "34", "author": "JF Kelvin", "year": "2016", "unstructured": "Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, et al. Cancer and fertility program improves patient satisfaction with information received. J Clin Oncol. 2016;34(15):1780\u20136.", "journal-title": "J Clin Oncol"}, {"issue": "9", "key": "13_CR4", "doi-asserted-by": "publisher", "first-page": "902", "DOI": "10.1056/NEJMra0801454", "volume": "360", "author": "JS Jeruss", "year": "2009", "unstructured": "Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902\u201311.", "journal-title": "N Engl J Med"}, {"issue": "13", "key": "13_CR5", "doi-asserted-by": "publisher", "first-page": "1670", "DOI": "10.1200/JCO.2010.31.2462", "volume": "29", "author": "M Peate", "year": "2011", "unstructured": "Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It\u2019s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer\u00a0\u2013 an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "13_CR6", "doi-asserted-by": "publisher", "first-page": "463", "DOI": "10.1038/nrurol.2013.145", "volume": "10", "author": "DJ Katz", "year": "2013", "unstructured": "Katz DJ, Kolon TF, Feldman DR, Mulhall JP. Fertility preservation strategies for male patients with cancer. Nat Rev Urol. 2013;10(8):463\u201372.", "journal-title": "Nat Rev Urol"}, {"issue": "12", "key": "13_CR7", "doi-asserted-by": "publisher", "first-page": "1607", "DOI": "10.1200/JCO.2010.33.7808", "volume": "29", "author": "W Hsiao", "year": "2011", "unstructured": "Hsiao W, Stahl PJ, Osterberg EC, Nejat E, Palermo GD, Rosenwaks Z, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction the Weill Cornell experience. J Clin Oncol. 2011;29(12):1607\u201311.", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "13_CR8", "doi-asserted-by": "publisher", "first-page": "398", "DOI": "10.1093/jnci/djq550", "volume": "103", "author": "O Stahl", "year": "2011", "unstructured": "Stahl O, Boyd HA, Giwercman A, Lindholm M, Jensen A, Kjaer SK, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst. 2011;103(5):398\u2013406.", "journal-title": "J Natl Cancer Inst"}, {"key": "13_CR9", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/s12916-015-0545-7", "volume": "14", "author": "M Lambertini", "year": "2016", "unstructured": "Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1\u201316.", "journal-title": "BMC Med"}, {"issue": "13", "key": "13_CR10", "doi-asserted-by": "publisher", "first-page": "3102", "DOI": "10.1002/cncr.25106", "volume": "116", "author": "P Sukumvanich", "year": "2010", "unstructured": "Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102\u201311.", "journal-title": "Cancer"}, {"issue": "5", "key": "13_CR11", "doi-asserted-by": "publisher", "first-page": "1635", "DOI": "10.1016/j.fertnstert.2007.09.048", "volume": "90", "author": "A Reh", "year": "2008", "unstructured": "Reh A, Oktem O. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635\u20139.", "journal-title": "Fertil Steril"}, {"issue": "5", "key": "13_CR12", "doi-asserted-by": "publisher", "first-page": "519", "DOI": "10.1177/1933719114549856", "volume": "22", "author": "A Iwase", "year": "2015", "unstructured": "Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci. 2015;22(5):519\u201326.", "journal-title": "Reprod Sci"}, {"issue": "19", "key": "13_CR13", "doi-asserted-by": "publisher", "first-page": "2500", "DOI": "10.1200/JCO.2013.49.2678", "volume": "31", "author": "AW Loren", "year": "2013", "unstructured": "Loren AW, Mangu PB, Beck LN, Brennan L, Madgalinsky AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500\u201310.", "journal-title": "J Clin Oncol"}, {"issue": "Suppl 6", "key": "13_CR14", "doi-asserted-by": "publisher", "first-page": "vi160", "DOI": "10.1093/annonc/mdt199", "volume": "24", "author": "FA Peccatori", "year": "2013", "unstructured": "Peccatori FA, Azim HA Jr, Orecchia R, Hokestra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practical guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160\u201370.", "journal-title": "Ann Oncol"}, {"issue": "6", "key": "13_CR15", "doi-asserted-by": "publisher", "first-page": "2125.e9", "DOI": "10.1016/j.fertnstert.2011.01.030", "volume": "95", "author": "M S\u00f6nmezer", "year": "2011", "unstructured": "S\u00f6nmezer M, T\u00fcrk\u00e7\u00fco\u011flu I, Co\u015fkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125.e9\u201311.", "journal-title": "Fertil Steril"}, {"issue": "22", "key": "13_CR16", "doi-asserted-by": "publisher", "first-page": "2424", "DOI": "10.1200/JCO.2014.59.3723", "volume": "33", "author": "K Oktay", "year": "2015", "unstructured": "Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment as ovarian stimulation in woman with breast cancer. J Clin Oncol. 2015;33(22):2424\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "16", "key": "13_CR17", "doi-asserted-by": "publisher", "first-page": "2630", "DOI": "10.1200/JCO.2007.14.8700", "volume": "26", "author": "AA Azim", "year": "2008", "unstructured": "Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630\u20135.", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "13_CR18", "doi-asserted-by": "publisher", "first-page": "1490", "DOI": "10.1016/j.ejca.2015.05.007", "volume": "51", "author": "O Goldrat", "year": "2015", "unstructured": "Goldrat O, Kroman N, Peccatori FA, Cordoba O, Pistilli B, Lidegaard O, et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015;51(12):1490\u20136.", "journal-title": "Eur J Cancer"}, {"key": "13_CR19", "doi-asserted-by": "publisher", "first-page": "1657", "DOI": "10.1056/NEJMra1614676", "volume": "377", "author": "J Donnez", "year": "2017", "unstructured": "Donnez J, Dolamnm M. Fertility preservation in women. N Engl J Med. 2017;377:1657\u201365.", "journal-title": "N Engl J Med"}, {"issue": "9967", "key": "13_CR20", "doi-asserted-by": "publisher", "first-page": "506", "DOI": "10.1016/S0140-6736(15)60198-2", "volume": "385", "author": "J Donnez", "year": "2015", "unstructured": "Donnez J, Dolmans M-M, Pellicer A, Diaz-Garcia C, Ernst E, Macklon KT, et al. Fertility preservation for age-related fertility decline. Lancet. 2015;385(9967):506\u20137.", "journal-title": "Lancet"}, {"issue": "9981", "key": "13_CR21", "doi-asserted-by": "publisher", "first-page": "1947", "DOI": "10.1016/S0140-6736(15)60960-6", "volume": "6/8", "author": "CY Andersen", "year": "2015", "unstructured": "Andersen CY. Success and challenges in fertility preservation after ovarian tissue grafting. Lancet. 2015;6/8(9981):1947\u20138.", "journal-title": "Lancet"}, {"issue": "16", "key": "13_CR22", "doi-asserted-by": "publisher", "first-page": "2908", "DOI": "10.1182/blood-2010-01-265751", "volume": "116", "author": "MM Dolmans", "year": "2010", "unstructured": "Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908\u201314.", "journal-title": "Blood"}, {"issue": "6", "key": "13_CR23", "doi-asserted-by": "publisher", "first-page": "2158", "DOI": "10.1016/j.fertnstert.2010.12.019", "volume": "95", "author": "M Rosendahl", "year": "2011", "unstructured": "Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158\u201361.", "journal-title": "Fertil Steril"}, {"issue": "10", "key": "13_CR24", "doi-asserted-by": "publisher", "first-page": "923", "DOI": "10.1056/NEJMoa1413204", "volume": "372", "author": "HCF Moore", "year": "2015", "unstructured": "Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923\u201332.", "journal-title": "N Engl J Med"}, {"issue": "3", "key": "13_CR25", "doi-asserted-by": "publisher", "first-page": "906-914.e4", "DOI": "10.1016/j.fertnstert.2010.11.017", "volume": "95", "author": "Mohamed A. Bedaiwy", "year": "2011", "unstructured": "Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906\u201314.e1\u20134.", "journal-title": "Fertility and Sterility"}, {"issue": "12", "key": "13_CR26", "first-page": "2408", "volume": "26", "author": "M Lambertini", "year": "2015", "unstructured": "Lambertini M, Ceppi M, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408\u201319.", "journal-title": "Ann Oncol"}, {"issue": "10", "key": "13_CR27", "doi-asserted-by": "publisher", "first-page": "2052", "DOI": "10.1093/annonc/mdq066", "volume": "21", "author": "K Behringer", "year": "2010", "unstructured": "Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052\u201360.", "journal-title": "Ann Oncol"}, {"issue": "22", "key": "13_CR28", "doi-asserted-by": "publisher", "first-page": "2568", "DOI": "10.1200/JCO.2015.65.8864", "volume": "34", "author": "I Demeestere", "year": "2016", "unstructured": "Demeestere I, Brice P, Fedro A, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of the gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long\u00a0\u2013 term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568\u201374.", "journal-title": "J Clin Oncol"}, {"issue": "35", "key": "13_CR29", "doi-asserted-by": "publisher", "first-page": "5952", "DOI": "10.1200/JCO.2009.23.0250", "volume": "27", "author": "GP Quinn", "year": "2009", "unstructured": "Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "11", "key": "13_CR30", "doi-asserted-by": "publisher", "first-page": "1244", "DOI": "10.1002/pon.2022", "volume": "21", "author": "GP Quinn", "year": "2012", "unstructured": "Quinn GP, Vadaparampil ST, Malo T, Reinecke J, Bower B, Albrecht T, et al. Oncologists\u2019 use of patient educational materials about cancer and fertility preservation. Psychooncology. 2012;21(11):1244\u20139. \nhttps://doi.org/10.1002/pon.2022\n\n.", "journal-title": "Psychooncology"}, {"issue": "6", "key": "13_CR31", "doi-asserted-by": "publisher", "first-page": "1710", "DOI": "10.1002/cncr.26459", "volume": "118", "author": "JM Letourneau", "year": "2011", "unstructured": "Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2011;118(6):1710\u20137. \nhttps://doi.org/10.1002/cncr.26459\n\n.", "journal-title": "Cancer"}, {"issue": "1", "key": "13_CR32", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1016/j.ejca.2010.09.007", "volume": "47", "author": "HA Azim Jr", "year": "2011", "unstructured": "Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74\u201383.", "journal-title": "Eur J Cancer"}, {"issue": "1", "key": "13_CR33", "doi-asserted-by": "publisher", "first-page": "73", "DOI": "10.1200/JCO.2012.44.2285", "volume": "31", "author": "HA Azim Jr", "year": "2013", "unstructured": "Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameyne L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "13_CR34", "doi-asserted-by": "publisher", "first-page": "249", "DOI": "10.1001/jamaoncol.2015.5610", "volume": "2", "author": "EM Fournier", "year": "2016", "unstructured": "Fournier EM. Oncofertility and the rights to future fertility. JAMA Oncol. 2016;2(2):249\u201352.", "journal-title": "JAMA Oncol"}], "container-title": ["Side Effects of Medical Cancer Therapy"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-70253-7_13", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 6, 27]], "date-time": "2018-06-27T15:13:06Z", "timestamp": 1530112386000}, "score": 22.807629, "issued": {"date-parts": [[2018]]}, "ISBN": ["9783319702520", "9783319702537"], "references-count": 34, "URL": "http://dx.doi.org/10.1007/978-3-319-70253-7_13", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T21:09:39Z", "timestamp": 1574284179388}, "reference-count": 29, "publisher": "Wiley", "issue": "3", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 11322, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1984, 9]]}, "DOI": "10.1111/j.1423-0410.1984.tb01592.x", "type": "journal-article", "created": {"date-parts": [[2009, 3, 5]], "date-time": "2009-03-05T23:19:01Z", "timestamp": 1236295141000}, "page": "242-249", "source": "Crossref", "is-referenced-by-count": 31, "title": ["Adverse Transfusion Reactions Associated with a Precipitating Anti-C4 Antibody of Anti-Rodgers Specificity"], "prefix": "10.1111", "volume": "47", "author": [{"given": "P.", "family": "Lambin", "sequence": "first", "affiliation": []}, {"given": "P.Y. Le", "family": "Pennec", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Hauptmann", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Desaint", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Habibi", "sequence": "additional", "affiliation": []}, {"given": "Ch.", "family": "Salmon", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB1", "doi-asserted-by": "crossref", "first-page": "312", "DOI": "10.1016/S0140-6736(68)90527-8", "article-title": "Anaphylactoid transfusion reactions associated with anti-IgA", "volume": "11", "author": "Vyas", "year": "1968", "journal-title": "Lancet"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB2", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1056/NEJM196901232800404", "article-title": "Anaphylactic transfusion reactions associated with anti-IgA antibody", "volume": "280", "author": "Schmidt", "year": "1969", "journal-title": "New Engl. J. Med."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB3", "doi-asserted-by": "crossref", "first-page": "2283", "DOI": "10.1172/JCI106194", "article-title": "Structural polymorphism of the fourth component of human complement", "volume": "48", "author": "Rosenfeld", "year": "1969", "journal-title": "J. clin. Invest."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB4", "author": "Rittner", "first-page": "945", "year": "1975", "volume-title": "Kissmeyer-Nielsen, Histocompatibility testing 1975"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB5", "doi-asserted-by": "crossref", "first-page": "5165", "DOI": "10.1073/pnas.75.10.5165", "article-title": "Tow HLA-linked loci controlling the fourth component of human complement", "volume": "75", "author": "O'Neill", "year": "1978", "journal-title": "Proc. natn. Acad. Sci."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB6", "doi-asserted-by": "crossref", "first-page": "668", "DOI": "10.1038/273668a0", "article-title": "Chido and Rodgers blood groups are distinct antigenic components of human complement C4", "volume": "273", "author": "O'Neill", "year": "1978", "journal-title": "Nature"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB7", "doi-asserted-by": "crossref", "first-page": "140", "DOI": "10.1111/j.1423-0410.1967.tb03078.x", "article-title": "A nebulous antibody responsible for cross-matching difficulties (Chido)", "volume": "12", "author": "Harris", "year": "1967", "journal-title": "Vox Sang."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB8", "doi-asserted-by": "crossref", "first-page": "366", "DOI": "10.1111/j.1399-0039.1974.tb00262.x", "article-title": "Linkage of Chido and HLA", "volume": "4", "author": "Middleton", "year": "1974", "journal-title": "Tissue Antigens"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB9", "first-page": "175", "article-title": "A new antibody specificity, anti Rga, reacting with a red cell and serum antigen", "volume": "30", "author": "Longster", "year": "1976", "journal-title": "Vox Sang."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB10", "doi-asserted-by": "crossref", "first-page": "143", "DOI": "10.1111/j.1399-0039.1976.tb00564.x", "article-title": "Rga (Rodgers) and the HLA region: linkage and associations", "volume": "8", "author": "Giles", "year": "1976", "journal-title": "Tissue Antigens"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB11", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1111/j.1423-0410.1976.tb02817.x", "article-title": "The HLA type of Rg(a-) individuals", "volume": "30", "author": "James", "year": "1976", "journal-title": "Vox Sang."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB12", "first-page": "32", "article-title": "The genetic control of Chido and Rodgers blood group substances", "volume": "18", "author": "O'Neill", "year": "1981", "journal-title": "Semin. Hematol."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB13", "doi-asserted-by": "crossref", "first-page": "713", "DOI": "10.1038/276713a0", "article-title": "Localisation of Chido and Rodgers determinants to the C4d fragment of human C4", "volume": "276", "author": "Tilley", "year": "1978", "journal-title": "Nature"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB14", "first-page": "181", "article-title": "Chido and Rodgers antigenic determinant on the fourth component of human complement", "volume": "128", "author": "Chu", "year": "1982", "journal-title": "J. Immun."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB15", "doi-asserted-by": "crossref", "first-page": "3576", "DOI": "10.1073/pnas.77.6.3576", "article-title": "Inherited structural polymorphism of the fourth component of human complement", "volume": "77", "author": "Awdeh", "year": "1980", "journal-title": "Proc. natn. Acad. Sci."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB16", "author": "Giles", "first-page": "268", "year": "1977", "volume-title": "Mohn. Human blood groups"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB17", "doi-asserted-by": "crossref", "first-page": "266", "DOI": "10.1046/j.1537-2995.1975.15375160363.x", "article-title": "Successful transfusion of Chido-positive blood to two patients with anti-Chido", "volume": "15", "author": "Moore", "year": "1975", "journal-title": "Transfusion"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB18", "doi-asserted-by": "crossref", "first-page": "169", "DOI": "10.1046/j.1537-2995.1977.17277151924.x", "article-title": "Red blood cell survival studies in patients with anti-Cha, anti-Yka, anti-Ge and anti-Vel", "volume": "17", "author": "Tilley", "year": "1977", "journal-title": "Transfusion"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB19", "doi-asserted-by": "crossref", "first-page": "179", "DOI": "10.1111/j.1423-0410.1979.tb02288.x", "article-title": "Survival studies of 51Cr Ch (a+) red blood cells in a patient with anti-Ch3 and massive transfusion of incompatible blood", "volume": "37", "author": "Nordhagen", "year": "1979", "journal-title": "Vox Sang."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB20", "author": "Steinbuch", "year": "1983", "article-title": "A simplified technique for the isolation of the fourth complement component", "journal-title": "Prep. Biochem."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB21", "first-page": "1115", "article-title": "A simple technique for the isolation of monoclonal IgG and IgA. Revue eur", "volume": "15", "author": "Fine", "year": "1970", "journal-title": "Etud. clin. Biol."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB22", "first-page": "274", "article-title": "A new rapid method for genetic typing of human immunoglobulins", "volume": "100", "author": "Vyas", "year": "1968", "journal-title": "J. Immun."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB23", "author": "Giles", "first-page": "33", "year": "1980", "volume-title": "Bell, A seminar on antigens on blood cells and body fluids"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB24", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1111/j.1423-0410.1981.tb01045.x", "article-title": "Differential coating of human red blood cells with C4 or C3 in a low ionic strength medium", "volume": "41", "author": "Heier", "year": "1981", "journal-title": "Vox Sang."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB25", "first-page": "587", "article-title": "Genetic polymorphism of human complement proteins", "volume": "22", "author": "Hauptmann", "year": "1979", "journal-title": "Revue fr. Transf. Imm.-h\u00e9mat."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB26", "doi-asserted-by": "crossref", "first-page": "1211", "DOI": "10.1073/pnas.64.4.1211", "article-title": "Am 1: The first genetic marker of human immunoglobulin A", "volume": "64", "author": "Vyas", "year": "1969", "journal-title": "Proc. natn. Acad. Sci."}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB27", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1046/j.1537-2995.1975.15175103503.x", "article-title": "Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the litterature", "volume": "15", "author": "Pineda", "year": "1975", "journal-title": "Transfusion"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB28", "first-page": "289", "article-title": "Anti-IgA in blood donors", "volume": "16", "author": "Vyas", "year": "1976", "journal-title": "Transfusion"}, {"key": "10.1111/j.1423-0410.1984.tb01592.x-BIB29", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1111/j.1423-0410.1977.tb00609.x", "article-title": "Weak anti-IgA antibodies with limited specificity and nonhemolytic transfusion reactions", "volume": "32", "author": "Koistinen", "year": "1977", "journal-title": "Vox Sang."}], "container-title": ["Vox Sanguinis"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1423-0410.1984.tb01592.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 18]], "date-time": "2019-02-18T05:34:02Z", "timestamp": 1550468042000}, "score": 22.74808, "issued": {"date-parts": [[1984, 9]]}, "references-count": 29, "journal-issue": {"published-print": {"date-parts": [[1984, 9]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1111/j.1423-0410.1984.tb01592.x", "relation": {"cites": []}, "ISSN": ["0042-9007", "1423-0410"], "issn-type": [{"value": "0042-9007", "type": "print"}, {"value": "1423-0410", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T07:11:17Z", "timestamp": 1574838677923}, "reference-count": 101, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2017, 10, 19]], "date-time": "2017-10-19T00:00:00Z", "timestamp": 1508371200000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2017, 10, 19]], "date-time": "2017-10-19T00:00:00Z", "timestamp": 1508371200000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["FEBS J"], "published-print": {"date-parts": [[2018, 2]]}, "DOI": "10.1111/febs.14277", "type": "journal-article", "created": {"date-parts": [[2017, 9, 22]], "date-time": "2017-09-22T08:38:06Z", "timestamp": 1506069486000}, "page": "763-776", "source": "Crossref", "is-referenced-by-count": 11, "title": ["A drug development perspective on targeting tumor-associated myeloid cells"], "prefix": "10.1111", "volume": "285", "author": [{"given": "Meher", "family": "Majety", "sequence": "first", "affiliation": [{"name": "Roche Pharmaceutical Research and Early Development; Roche Innovation Center Munich; Penzberg Germany"}]}, {"given": "Valeria", "family": "Runza", "sequence": "additional", "affiliation": [{"name": "Roche Pharmaceutical Research and Early Development; Roche Innovation Center Munich; Penzberg Germany"}]}, {"given": "Christian", "family": "Lehmann", "sequence": "additional", "affiliation": [{"name": "Roche Pharmaceutical Research and Early Development; Roche Innovation Center Munich; Penzberg Germany"}]}, {"given": "Sabine", "family": "Hoves", "sequence": "additional", "affiliation": [{"name": "Roche Pharmaceutical Research and Early Development; Roche Innovation Center Munich; Penzberg Germany"}]}, {"given": "Carola H.", "family": "Ries", "sequence": "additional", "affiliation": [{"name": "Roche Pharmaceutical Research and Early Development; Roche Innovation Center Munich; Penzberg Germany"}]}], "member": "311", "published-online": {"date-parts": [[2017, 10, 19]]}, "reference": [{"key": "10.1111/febs.14277-BIB0001|febs14277-cit-0001", "doi-asserted-by": "crossref", "first-page": "723", "DOI": "10.1038/nri3073", "article-title": "Protective and pathogenic functions of macrophage subsets", "volume": "11", "author": "Murray", "year": "2011", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/febs.14277-BIB0002|febs14277-cit-0002", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1172/JCI59643", "article-title": "Macrophage plasticity and polarization: in\u00a0vivo veritas", "volume": "122", "author": "Sica", "year": "2012", "journal-title": "J Clin Invest"}, {"key": "10.1111/febs.14277-BIB0003|febs14277-cit-0003", "author": "Binnemars-Postma", "volume": "18", "year": "2017", "article-title": "Nanomedicine strategies to target tumor-associated macrophages", "journal-title": "Int J Mol Sci", "DOI": "10.3390/ijms18050979", "doi-asserted-by": "crossref"}, {"key": "10.1111/febs.14277-BIB0004|febs14277-cit-0004", "doi-asserted-by": "crossref", "first-page": "3241", "DOI": "10.1158/1078-0432.CCR-16-3122", "article-title": "The promise of targeting macrophages in cancer therapy", "volume": "23", "author": "Brown", "year": "2017", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/febs.14277-BIB0005|febs14277-cit-0005", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.1038/nrclinonc.2016.217", "article-title": "Tumour-associated macrophages as treatment targets in oncology", "volume": "14", "author": "Mantovani", "year": "2017", "journal-title": "Nat Rev Clin Oncol"}, {"key": "10.1111/febs.14277-BIB0006|febs14277-cit-0006", "doi-asserted-by": "crossref", "first-page": "206", "DOI": "10.1016/j.addr.2017.04.010", "article-title": "Progress in tumor-associated macrophage (TAM)-targeted therapeutics", "volume": "114", "author": "Ngambenjawong", "year": "2017", "journal-title": "Adv Drug Deliv Rev"}, {"key": "10.1111/febs.14277-BIB0007|febs14277-cit-0007", "doi-asserted-by": "crossref", "first-page": "254", "DOI": "10.1002/path.1027", "article-title": "The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies", "volume": "196", "author": "Bingle", "year": "2002", "journal-title": "J Pathol"}, {"key": "10.1111/febs.14277-BIB0008|febs14277-cit-0008", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.3389/fonc.2014.00137", "article-title": "Tumor-associated macrophages contribute to tumor progression in ovarian cancer", "volume": "4", "author": "Colvin", "year": "2014", "journal-title": "Front Oncol"}, {"key": "10.1111/febs.14277-BIB0009|febs14277-cit-0009", "doi-asserted-by": "crossref", "first-page": "3142", "DOI": "10.1245/s10434-014-3601-1", "article-title": "Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma", "volume": "21", "author": "Xu", "year": "2014", "journal-title": "Ann Surg Oncol"}, {"key": "10.1111/febs.14277-BIB0010|febs14277-cit-0010", "doi-asserted-by": "crossref", "first-page": "e50946", "DOI": "10.1371/journal.pone.0050946", "article-title": "Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature", "volume": "7", "author": "Zhang", "year": "2012", "journal-title": "PLoS One"}, {"key": "10.1111/febs.14277-BIB0011|febs14277-cit-0011", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.12703/P6-13", "article-title": "The M1 and M2 paradigm of macrophage activation: time for reassessment", "volume": "6", "author": "Martinez", "year": "2014", "journal-title": "F1000Prime Rep"}, {"key": "10.1111/febs.14277-BIB0012|febs14277-cit-0012", "doi-asserted-by": "crossref", "first-page": "14", "DOI": "10.1016/j.immuni.2014.06.008", "article-title": "Macrophage activation and polarization: nomenclature and experimental guidelines", "volume": "41", "author": "Murray", "year": "2014", "journal-title": "Immunity"}, {"key": "10.1111/febs.14277-BIB0013|febs14277-cit-0013", "doi-asserted-by": "crossref", "first-page": "208", "DOI": "10.1016/j.it.2016.01.004", "article-title": "The nature of myeloid-derived suppressor cells in the tumor microenvironment", "volume": "37", "author": "Kumar", "year": "2016", "journal-title": "Trends Immunol"}, {"key": "10.1111/febs.14277-BIB0014|febs14277-cit-0014", "doi-asserted-by": "crossref", "first-page": "3356", "DOI": "10.1172/JCI80005", "article-title": "Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected", "volume": "125", "author": "Marvel", "year": "2015", "journal-title": "J Clin Invest"}, {"key": "10.1111/febs.14277-BIB0015|febs14277-cit-0015", "doi-asserted-by": "crossref", "first-page": "889", "DOI": "10.1038/ni.1937", "article-title": "Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm", "volume": "11", "author": "Biswas", "year": "2010", "journal-title": "Nat Immunol"}, {"key": "10.1111/febs.14277-BIB0016|febs14277-cit-0016", "doi-asserted-by": "crossref", "first-page": "462", "DOI": "10.1016/j.ccell.2015.02.015", "article-title": "Macrophages and therapeutic resistance in cancer", "volume": "27", "author": "Ruffell", "year": "2015", "journal-title": "Cancer Cell"}, {"key": "10.1111/febs.14277-BIB0017|febs14277-cit-0017", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1038/nm.3794", "article-title": "Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer", "volume": "21", "author": "Bronte", "year": "2015", "journal-title": "Nat Med"}, {"key": "10.1111/febs.14277-BIB0018|febs14277-cit-0018", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1046/j.1365-2249.1996.d01-4.x", "article-title": "Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages", "volume": "103", "author": "Audran", "year": "1996", "journal-title": "Clin Exp Immunol"}, {"key": "10.1111/febs.14277-BIB0019|febs14277-cit-0019", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1016/j.coi.2005.11.006", "article-title": "Colony-stimulating factor-1 in immunity and inflammation", "volume": "18", "author": "Chitu", "year": "2006", "journal-title": "Curr Opin Immunol"}, {"key": "10.1111/febs.14277-BIB0020|febs14277-cit-0020", "doi-asserted-by": "crossref", "first-page": "12150", "DOI": "10.1038/ncomms12150", "article-title": "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards", "volume": "7", "author": "Bronte", "year": "2016", "journal-title": "Nat Commun"}, {"key": "10.1111/febs.14277-BIB0021|febs14277-cit-0021", "doi-asserted-by": "crossref", "first-page": "431", "DOI": "10.1038/nrc.2016.52", "article-title": "Neutrophils in cancer: neutral no more", "volume": "16", "author": "Coffelt", "year": "2016", "journal-title": "Nat Rev Cancer"}, {"key": "10.1111/febs.14277-BIB0022|febs14277-cit-0022", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1016/j.cell.2016.02.065", "article-title": "Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma", "volume": "165", "author": "Hugo", "year": "2016", "journal-title": "Cell"}, {"key": "10.1111/febs.14277-BIB0023|febs14277-cit-0023", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1016/j.ccr.2013.01.008", "article-title": "Role of macrophage targeting in the antitumor activity of trabectedin", "volume": "23", "author": "Germano", "year": "2013", "journal-title": "Cancer Cell"}, {"key": "10.1111/febs.14277-BIB0024|febs14277-cit-0024", "doi-asserted-by": "crossref", "first-page": "3955", "DOI": "10.1182/blood-2010-02-266296", "article-title": "An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation", "volume": "116", "author": "MacDonald", "year": "2010", "journal-title": "Blood"}, {"key": "10.1111/febs.14277-BIB0025|febs14277-cit-0025", "doi-asserted-by": "crossref", "first-page": "846", "DOI": "10.1016/j.ccr.2014.05.016", "article-title": "Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy", "volume": "25", "author": "Ries", "year": "2014", "journal-title": "Cancer Cell"}, {"key": "10.1111/febs.14277-BIB0026|febs14277-cit-0026", "doi-asserted-by": "crossref", "first-page": "428", "DOI": "10.1056/NEJMoa1411366", "article-title": "Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor", "volume": "373", "author": "Tap", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/febs.14277-BIB0027|febs14277-cit-0027", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.1016/j.cellimm.2014.03.019", "article-title": "Monocyte subsets in man and other species", "volume": "289", "author": "Ziegler-Heitbrock", "year": "2014", "journal-title": "Cell Immunol"}, {"key": "10.1111/febs.14277-BIB0028|febs14277-cit-0028", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1007/s11864-015-0385-x", "article-title": "Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis", "volume": "17", "author": "Brahmi", "year": "2016", "journal-title": "Curr Treat Options Oncol"}, {"key": "10.1111/febs.14277-BIB0029|febs14277-cit-0029", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1016/j.coph.2015.05.008", "article-title": "CSF-1/CSF-1R targeting agents in clinical development for cancer therapy", "volume": "23", "author": "Ries", "year": "2015", "journal-title": "Curr Opin Pharmacol"}, {"key": "10.1111/febs.14277-BIB0030|febs14277-cit-0030", "doi-asserted-by": "crossref", "first-page": "329", "DOI": "10.1593/neo.07871", "article-title": "Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response", "volume": "10", "author": "Pahler", "year": "2008", "journal-title": "Neoplasia"}, {"key": "10.1111/febs.14277-BIB0031|febs14277-cit-0031", "doi-asserted-by": "crossref", "first-page": "577", "DOI": "10.1016/j.celrep.2015.03.055", "article-title": "Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy", "volume": "11", "author": "Rivera", "year": "2015", "journal-title": "Cell Rep"}, {"key": "10.1111/febs.14277-BIB0032|febs14277-cit-0032", "doi-asserted-by": "crossref", "first-page": "aad3018", "DOI": "10.1126/science.aad3018", "article-title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas", "volume": "352", "author": "Quail", "year": "2016", "journal-title": "Science"}, {"key": "10.1111/febs.14277-BIB0033|febs14277-cit-0033", "doi-asserted-by": "crossref", "first-page": "949", "DOI": "10.1016/S1470-2045(15)00132-1", "article-title": "CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study", "volume": "16", "author": "Cassier", "year": "2015", "journal-title": "Lancet Oncol"}, {"key": "10.1111/febs.14277-BIB0034|febs14277-cit-0034", "doi-asserted-by": "crossref", "first-page": "53", "DOI": "10.1186/s40425-017-0257-y", "article-title": "Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy", "volume": "5", "author": "Cannarile", "year": "2017", "journal-title": "J Immunother Cancer"}, {"key": "10.1111/febs.14277-BIB0035|febs14277-cit-0035", "doi-asserted-by": "crossref", "first-page": "5703", "DOI": "10.1158/1078-0432.CCR-16-3261", "article-title": "First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors", "volume": "23", "author": "Papadopoulos", "year": "2017", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/febs.14277-BIB0036|febs14277-cit-0036", "doi-asserted-by": "crossref", "first-page": "1752", "DOI": "10.3899/jrheum.141580", "article-title": "Results from a Phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy", "volume": "42", "author": "Genovese", "year": "2015", "journal-title": "J Rheumatol"}, {"key": "10.1111/febs.14277-BIB0037|febs14277-cit-0037", "doi-asserted-by": "crossref", "first-page": "1155", "DOI": "10.2147/OTT.S127955", "article-title": "Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas", "volume": "10", "author": "Recine", "year": "2017", "journal-title": "Onco Targets Ther"}, {"key": "10.1111/febs.14277-BIB0038|febs14277-cit-0038", "doi-asserted-by": "crossref", "first-page": "313", "DOI": "10.1080/14656566.2017.1285282", "article-title": "The efficacy of trabectedin in treating ovarian cancer", "volume": "18", "author": "Teplinsky", "year": "2017", "journal-title": "Expert Opin Pharmacother"}, {"key": "10.1111/febs.14277-BIB0039|febs14277-cit-0039", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.4103/2395-3977.200858", "article-title": "Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide", "volume": "3", "author": "Hindi", "year": "2017", "journal-title": "Cancer Transl Med"}, {"key": "10.1111/febs.14277-BIB0040|febs14277-cit-0040", "doi-asserted-by": "crossref", "first-page": "105", "DOI": "10.1517/13543784.2016.1124086", "article-title": "Trabectedin for the treatment of breast cancer", "volume": "25", "author": "D'Incalci", "year": "2016", "journal-title": "Expert Opin Investig Drugs"}, {"key": "10.1111/febs.14277-BIB0041|febs14277-cit-0041", "doi-asserted-by": "crossref", "first-page": "1234", "DOI": "10.1093/annonc/mdr399", "article-title": "Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer", "volume": "23", "author": "Michaelson", "year": "2012", "journal-title": "Ann Oncol"}, {"key": "10.1111/febs.14277-BIB0042|febs14277-cit-0042", "doi-asserted-by": "crossref", "first-page": "646", "DOI": "10.1038/bjc.2014.149", "article-title": "Trabectedin, a drug acting on both cancer cells and the tumour microenvironment", "volume": "111", "author": "D'Incalci", "year": "2014", "journal-title": "Br J Cancer"}, {"key": "10.1111/febs.14277-BIB0043|febs14277-cit-0043", "doi-asserted-by": "crossref", "first-page": "8155", "DOI": "10.1158/0008-5472.CAN-06-0179", "article-title": "Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin", "volume": "66", "author": "Herrero", "year": "2006", "journal-title": "Cancer Res"}, {"key": "10.1111/febs.14277-BIB0044|febs14277-cit-0044", "doi-asserted-by": "crossref", "first-page": "663", "DOI": "10.1007/s00280-015-2918-1", "article-title": "Unique features of trabectedin mechanism of action", "volume": "77", "author": "Larsen", "year": "2016", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "10.1111/febs.14277-BIB0045|febs14277-cit-0045", "doi-asserted-by": "crossref", "first-page": "2964", "DOI": "10.1158/0008-5472.CAN-04-4037", "article-title": "Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): inhibition of macrophage differentiation and cytokine production", "volume": "65", "author": "Allavena", "year": "2005", "journal-title": "Cancer Res"}, {"key": "10.1111/febs.14277-BIB0046|febs14277-cit-0046", "doi-asserted-by": "crossref", "first-page": "2235", "DOI": "10.1158/0008-5472.CAN-09-2335", "article-title": "Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells", "volume": "70", "author": "Germano", "year": "2010", "journal-title": "Cancer Res"}, {"key": "10.1111/febs.14277-BIB0047|febs14277-cit-0047", "doi-asserted-by": "crossref", "first-page": "335", "DOI": "10.1038/bjc.2016.424", "article-title": "Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms", "volume": "116", "author": "Romano", "year": "2017", "journal-title": "Br J Cancer"}, {"key": "10.1111/febs.14277-BIB0048|febs14277-cit-0048", "doi-asserted-by": "crossref", "first-page": "259", "DOI": "10.1016/j.cyto.2015.02.011", "article-title": "Targeting chemokines: pathogens can, why can't we?", "volume": "74", "author": "Proudfoot", "year": "2015", "journal-title": "Cytokine"}, {"key": "10.1111/febs.14277-BIB0049|febs14277-cit-0049", "doi-asserted-by": "crossref", "first-page": "522", "DOI": "10.1093/jnci/djq044", "article-title": "Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth", "volume": "102", "author": "Zhang", "year": "2010", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1111/febs.14277-BIB0050|febs14277-cit-0050", "first-page": "28697", "article-title": "Targeting the CCL2-CCR2 signaling axis in cancer metastasis", "volume": "19", "author": "Lim", "year": "2016", "journal-title": "Oncotarget"}, {"key": "10.1111/febs.14277-BIB0051|febs14277-cit-0051", "first-page": "49349", "article-title": "Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment", "volume": "31", "author": "Fang", "year": "2016", "journal-title": "Oncotarget"}, {"key": "10.1111/febs.14277-BIB0052|febs14277-cit-0052", "doi-asserted-by": "crossref", "first-page": "230", "DOI": "10.1165/rcmb.2010-0080OC", "article-title": "Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells", "volume": "44", "author": "Fridlender", "year": "2011", "journal-title": "Am J Respir Cell Mol Biol"}, {"key": "10.1111/febs.14277-BIB0053|febs14277-cit-0053", "doi-asserted-by": "crossref", "first-page": "2664", "DOI": "10.1158/0008-5472.CAN-10-3055", "article-title": "COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells", "volume": "71", "author": "Fujita", "year": "2011", "journal-title": "Cancer Res"}, {"key": "10.1111/febs.14277-BIB0054|febs14277-cit-0054", "doi-asserted-by": "crossref", "first-page": "1371", "DOI": "10.1172/JCI66236", "article-title": "Host immunity contributes to the anti-melanoma activity of BRAF inhibitors", "volume": "123", "author": "Knight", "year": "2013", "journal-title": "J Clin Invest"}, {"key": "10.1111/febs.14277-BIB0055|febs14277-cit-0055", "doi-asserted-by": "crossref", "first-page": "1231", "DOI": "10.1016/j.molonc.2014.03.016", "article-title": "Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers", "volume": "8", "author": "Moisan", "year": "2014", "journal-title": "Mol Oncol"}, {"key": "10.1111/febs.14277-BIB0056|febs14277-cit-0056", "doi-asserted-by": "crossref", "first-page": "312", "DOI": "10.1158/1535-7163.MCT-16-0124", "article-title": "Blocking the CCL2-CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model", "volume": "16", "author": "Teng", "year": "2017", "journal-title": "Mol Cancer Ther"}, {"key": "10.1111/febs.14277-BIB0057|febs14277-cit-0057", "first-page": "433", "article-title": "CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity", "volume": "70", "author": "Qian", "year": "2010", "journal-title": "Prostate"}, {"key": "10.1111/febs.14277-BIB0058|febs14277-cit-0058", "doi-asserted-by": "crossref", "first-page": "810", "DOI": "10.1038/modpathol.2016.78", "article-title": "Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers", "volume": "8", "author": "Yao", "year": "2016", "journal-title": "Mod Pathol"}, {"key": "10.1111/febs.14277-BIB0059|febs14277-cit-0059", "doi-asserted-by": "crossref", "first-page": "760", "DOI": "10.1007/s10637-012-9869-8", "article-title": "Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer", "volume": "31", "author": "Pienta", "year": "2013", "journal-title": "Invest New Drugs"}, {"key": "10.1111/febs.14277-BIB0060|febs14277-cit-0060", "doi-asserted-by": "crossref", "first-page": "1020", "DOI": "10.1002/jcph.140", "article-title": "Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data", "volume": "53", "author": "Fetterly", "year": "2013", "journal-title": "J Clin Pharmacol"}, {"key": "10.1111/febs.14277-BIB0061|febs14277-cit-0061", "doi-asserted-by": "crossref", "first-page": "829", "DOI": "10.1080/19420862.2015.1060384", "article-title": "Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys", "volume": "7", "author": "Dudal", "year": "2015", "journal-title": "MAbs"}, {"key": "10.1111/febs.14277-BIB0062|febs14277-cit-0062", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.4161/mabs.2.5.12833", "article-title": "Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets", "volume": "2", "author": "Davda", "year": "2010", "journal-title": "MAbs"}, {"key": "10.1111/febs.14277-BIB0063|febs14277-cit-0063", "doi-asserted-by": "crossref", "first-page": "130", "DOI": "10.1038/nature13862", "article-title": "Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis", "volume": "515", "author": "Bonapace", "year": "2014", "journal-title": "Nature"}, {"key": "10.1111/febs.14277-BIB0064|febs14277-cit-0064", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1038/nature13931", "article-title": "Cancer: metastasis risk after anti-macrophage therapy", "volume": "515", "author": "Keklikoglou", "year": "2014", "journal-title": "Nature"}, {"key": "10.1111/febs.14277-BIB0065|febs14277-cit-0065", "doi-asserted-by": "crossref", "first-page": "651", "DOI": "10.1016/S1470-2045(16)00078-4", "article-title": "Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial", "volume": "17", "author": "Nywening", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/febs.14277-BIB0066|febs14277-cit-0066", "first-page": "307", "article-title": "C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria", "volume": "2", "author": "Menne", "year": "2016", "journal-title": "Nephrol Dial Transplant"}, {"key": "10.1111/febs.14277-BIB0067|febs14277-cit-0067", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1146/annurev.immunol.22.012703.104533", "article-title": "CD40/CD154 interactions at the interface of tolerance and immunity", "volume": "22", "author": "Quezada", "year": "2004", "journal-title": "Annu Rev Immunol"}, {"key": "10.1111/febs.14277-BIB0068|febs14277-cit-0068", "doi-asserted-by": "crossref", "first-page": "1612", "DOI": "10.1126/science.1198443", "article-title": "CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans", "volume": "331", "author": "Beatty", "year": "2011", "journal-title": "Science"}, {"key": "10.1111/febs.14277-BIB0069|febs14277-cit-0069", "doi-asserted-by": "crossref", "first-page": "400", "DOI": "10.1158/2159-8290.CD-15-1032", "article-title": "IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma", "volume": "6", "author": "Long", "year": "2016", "journal-title": "Cancer Discov"}, {"key": "10.1111/febs.14277-BIB0070|febs14277-cit-0070", "doi-asserted-by": "crossref", "first-page": "175", "DOI": "10.1080/14737140.2017.1270208", "article-title": "Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists", "volume": "17", "author": "Beatty", "year": "2017", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "10.1111/febs.14277-BIB0071|febs14277-cit-0071", "doi-asserted-by": "crossref", "first-page": "140", "DOI": "10.1038/nrd4204", "article-title": "PI3K and cancer: lessons, challenges and opportunities", "volume": "13", "author": "Fruman", "year": "2014", "journal-title": "Nat Rev Drug Discov"}, {"key": "10.1111/febs.14277-BIB0072|febs14277-cit-0072", "doi-asserted-by": "crossref", "first-page": "391", "DOI": "10.3389/fphys.2014.00391", "article-title": "Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts", "volume": "5", "author": "Falasca", "year": "2014", "journal-title": "Front Physiol"}, {"key": "10.1111/febs.14277-BIB0073|febs14277-cit-0073", "doi-asserted-by": "crossref", "first-page": "443", "DOI": "10.1038/nature20554", "article-title": "Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells", "volume": "539", "author": "Henau", "year": "2016", "journal-title": "Nature"}, {"key": "10.1111/febs.14277-BIB0074|febs14277-cit-0074", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.1038/nature19834", "article-title": "PI3Kgamma is a molecular switch that controls immune suppression", "volume": "539", "author": "Kaneda", "year": "2016", "journal-title": "Nature"}, {"key": "10.1111/febs.14277-BIB0075|febs14277-cit-0075", "doi-asserted-by": "crossref", "first-page": "a008748", "DOI": "10.1101/cshperspect.a008748", "article-title": "Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion", "volume": "5", "author": "Hochreiter-Hufford", "year": "2013", "journal-title": "Cold Spring Harb Perspect Biol"}, {"key": "10.1111/febs.14277-BIB0076|febs14277-cit-0076", "doi-asserted-by": "crossref", "first-page": "285", "DOI": "10.1038/cmi.2010.83", "article-title": "CD47: a new player in phagocytosis and xenograft rejection", "volume": "8", "author": "Navarro-Alvarez", "year": "2011", "journal-title": "Cell Mol Immunol"}, {"key": "10.1111/febs.14277-BIB0077|febs14277-cit-0077", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1016/j.ejca.2017.02.013", "article-title": "Cancer immunotherapy targeting the CD47/SIRPalpha axis", "volume": "76", "author": "Weiskopf", "year": "2017", "journal-title": "Eur J Cancer"}, {"key": "10.1111/febs.14277-BIB0078|febs14277-cit-0078", "doi-asserted-by": "crossref", "first-page": "1209", "DOI": "10.1038/nm.3931", "article-title": "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors", "volume": "21", "author": "Liu", "year": "2015", "journal-title": "Nat Med"}, {"key": "10.1111/febs.14277-BIB0079|febs14277-cit-0079", "doi-asserted-by": "crossref", "first-page": "1122", "DOI": "10.1038/nm.3965", "article-title": "CD47 blockade as another immune checkpoint therapy for cancer", "volume": "21", "author": "Vonderheide", "year": "2015", "journal-title": "Nat Med"}, {"key": "10.1111/febs.14277-BIB0080|febs14277-cit-0080", "doi-asserted-by": "crossref", "first-page": "Abstract 3019", "DOI": "10.1200/JCO.2016.34.15_suppl.3019", "article-title": "A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers", "volume": "34", "author": "Sikic", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "10.1111/febs.14277-BIB0081|febs14277-cit-0081", "doi-asserted-by": "crossref", "first-page": "493", "DOI": "10.1038/nature22076", "article-title": "SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin", "volume": "544", "author": "Chen", "year": "2017", "journal-title": "Nature"}, {"key": "10.1111/febs.14277-BIB0082|febs14277-cit-0082", "doi-asserted-by": "crossref", "first-page": "842", "DOI": "10.2174/138945008785909310", "article-title": "CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling", "volume": "9", "author": "Sarfati", "year": "2008", "journal-title": "Curr Drug Targets"}, {"key": "10.1111/febs.14277-BIB0083|febs14277-cit-0083", "doi-asserted-by": "crossref", "first-page": "2741", "DOI": "10.1182/blood.V97.9.2741", "article-title": "Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells", "volume": "97", "author": "Seiffert", "year": "2001", "journal-title": "Blood"}, {"key": "10.1111/febs.14277-BIB0084|febs14277-cit-0084", "doi-asserted-by": "crossref", "first-page": "130", "DOI": "10.1016/S0962-8924(00)01906-1", "article-title": "Integrin-associated protein (CD47) and its ligands", "volume": "11", "author": "Brown", "year": "2001", "journal-title": "Trends Cell Biol"}, {"key": "10.1111/febs.14277-BIB0085|febs14277-cit-0085", "doi-asserted-by": "crossref", "first-page": "252", "DOI": "10.3389/fphar.2015.00252", "article-title": "Original insights on thrombospondin-1-related antireceptor strategies in cancer", "volume": "6", "author": "Jeanne", "year": "2015", "journal-title": "Front Pharmacol"}, {"key": "10.1111/febs.14277-BIB0086|febs14277-cit-0086", "first-page": "22406", "article-title": "CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis", "volume": "14", "author": "Gao", "year": "2016", "journal-title": "Oncotarget"}, {"key": "10.1111/febs.14277-BIB0087|febs14277-cit-0087", "doi-asserted-by": "crossref", "first-page": "493", "DOI": "10.1189/jlb.3A1215-546RR", "article-title": "Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47-/- mice from EAE", "volume": "101", "author": "Azcutia", "year": "2017", "journal-title": "J Leukoc Biol"}, {"key": "10.1111/febs.14277-BIB0088|febs14277-cit-0088", "doi-asserted-by": "crossref", "first-page": "e41972", "DOI": "10.1371/journal.pone.0041972", "article-title": "CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice", "volume": "7", "author": "Van", "year": "2012", "journal-title": "PLoS One"}, {"key": "10.1111/febs.14277-BIB0089|febs14277-cit-0089", "doi-asserted-by": "crossref", "first-page": "E168", "DOI": "10.21037/jtd.2017.02.30", "article-title": "Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy", "volume": "9", "author": "Huang", "year": "2017", "journal-title": "J Thorac Dis"}, {"key": "10.1111/febs.14277-BIB0090|febs14277-cit-0090", "doi-asserted-by": "crossref", "first-page": "61", "DOI": "10.1111/imm.12290", "article-title": "Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity-implications for engraftment of human cells", "volume": "143", "author": "Kwong", "year": "2014", "journal-title": "Immunology"}, {"key": "10.1111/febs.14277-BIB0091|febs14277-cit-0091", "doi-asserted-by": "crossref", "first-page": "699", "DOI": "10.1016/j.cell.2010.07.044", "article-title": "Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma", "volume": "142", "author": "Chao", "year": "2010", "journal-title": "Cell"}, {"key": "10.1111/febs.14277-BIB0092|febs14277-cit-0092", "doi-asserted-by": "crossref", "first-page": "18342", "DOI": "10.1073/pnas.1106550108", "article-title": "CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction", "volume": "108", "author": "Zhao", "year": "2011", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/febs.14277-BIB0093|febs14277-cit-0093", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.4049/jimmunol.1401719", "article-title": "Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages", "volume": "195", "author": "Lv", "year": "2015", "journal-title": "J Immunol"}, {"key": "10.1111/febs.14277-BIB0094|febs14277-cit-0094", "doi-asserted-by": "crossref", "first-page": "523", "DOI": "10.1016/j.ymthe.2016.11.006", "article-title": "Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies", "volume": "25", "author": "Dheilly", "year": "2017", "journal-title": "Mol Ther"}, {"key": "10.1111/febs.14277-BIB0095|febs14277-cit-0095", "doi-asserted-by": "crossref", "first-page": "946", "DOI": "10.1080/19420862.2015.1062192", "article-title": "A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells", "volume": "7", "author": "Piccione", "year": "2015", "journal-title": "MAbs"}, {"key": "10.1111/febs.14277-BIB0096|febs14277-cit-0096", "doi-asserted-by": "crossref", "first-page": "5109", "DOI": "10.1158/1078-0432.CCR-15-2503", "article-title": "SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells", "volume": "22", "author": "Piccione", "year": "2016", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/febs.14277-BIB0097|febs14277-cit-0097", "doi-asserted-by": "crossref", "first-page": "e89140", "DOI": "10.1172/jci.insight.89140", "article-title": "Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy", "volume": "2", "author": "Yanagita", "year": "2017", "journal-title": "JCI Insight"}, {"key": "10.1111/febs.14277-BIB0098|febs14277-cit-0098", "doi-asserted-by": "crossref", "first-page": "736", "DOI": "10.1016/j.cell.2017.04.016", "article-title": "An immune atlas of clear cell renal cell carcinoma", "volume": "169", "author": "Chevrier", "year": "2017", "journal-title": "Cell"}, {"key": "10.1111/febs.14277-BIB0099|febs14277-cit-0099", "doi-asserted-by": "crossref", "first-page": "750", "DOI": "10.1016/j.cell.2017.04.014", "article-title": "Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses", "volume": "169", "author": "Lavin", "year": "2017", "journal-title": "Cell"}, {"key": "10.1111/febs.14277-BIB0100|febs14277-cit-0100", "doi-asserted-by": "crossref", "first-page": "551", "DOI": "10.1038/nm.4308", "article-title": "VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer", "volume": "23", "author": "Gao", "year": "2017", "journal-title": "Nat Med"}, {"key": "10.1111/febs.14277-BIB0101|febs14277-cit-0101", "doi-asserted-by": "crossref", "first-page": "203", "DOI": "10.1016/j.celrep.2017.03.037", "article-title": "Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis", "volume": "19", "author": "Tsujikawa", "year": "2017", "journal-title": "Cell Rep"}], "container-title": ["The FEBS Journal"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ffebs.14277", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/febs.14277/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 3]], "date-time": "2019-10-03T21:06:17Z", "timestamp": 1570136777000}, "score": 22.585043, "issued": {"date-parts": [[2017, 10, 19]]}, "references-count": 101, "journal-issue": {"published-print": {"date-parts": [[2018, 2]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1111/febs.14277", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1742-464X"], "issn-type": [{"value": "1742-464X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T13:58:45Z", "timestamp": 1574690325446}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2015, 1, 1]]}, "DOI": "10.1158/1538-7445.chtme14-pr04", "type": "proceedings-article", "created": {"date-parts": [[2015, 5, 1]], "date-time": "2015-05-01T21:31:45Z", "timestamp": 1430515905000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract PR04: Targeting tumor-asoociated macrophages with a novel anti-CSF1R antibody in cancer patients"], "prefix": "10.1158", "author": [{"given": "Michael", "family": "Cannarile", "sequence": "first", "affiliation": []}, {"given": "Sabine", "family": "Hoves", "sequence": "additional", "affiliation": []}, {"given": "Ann-Marie", "family": "Broeske", "sequence": "additional", "affiliation": []}, {"given": "Joerg", "family": "Benz", "sequence": "additional", "affiliation": []}, {"given": "Katharina", "family": "Wartha", "sequence": "additional", "affiliation": []}, {"given": "Valeria", "family": "Runza", "sequence": "additional", "affiliation": []}, {"given": "Flora", "family": "Rey-Giraud", "sequence": "additional", "affiliation": []}, {"given": "Leon P.", "family": "Pradel", "sequence": "additional", "affiliation": []}, {"given": "Friedrich", "family": "Feuerhake", "sequence": "additional", "affiliation": []}, {"given": "Irina", "family": "Klaman", "sequence": "additional", "affiliation": []}, {"given": "Tobin", "family": "Jones", "sequence": "additional", "affiliation": []}, {"given": "Ute", "family": "Jucknischke", "sequence": "additional", "affiliation": []}, {"given": "Stefan", "family": "Scheiblich", "sequence": "additional", "affiliation": []}, {"given": "Ingo H.", "family": "Gorr", "sequence": "additional", "affiliation": []}, {"given": "Antje", "family": "Walz", "sequence": "additional", "affiliation": []}, {"given": "Keelara", "family": "Abiraj", "sequence": "additional", "affiliation": []}, {"given": "Philippe", "family": "Cassier", "sequence": "additional", "affiliation": []}, {"given": "Antonio", "family": "Sica", "sequence": "additional", "affiliation": []}, {"given": "Carlos", "family": "Gomez-Roca", "sequence": "additional", "affiliation": []}, {"given": "Christophe Le", "family": "Tourneau", "sequence": "additional", "affiliation": []}, {"given": "Jean-Pierre", "family": "Delord", "sequence": "additional", "affiliation": []}, {"given": "Antoine", "family": "Italiano", "sequence": "additional", "affiliation": []}, {"given": "Hyam", "family": "Levitsky", "sequence": "additional", "affiliation": []}, {"given": "Jean-Yves", "family": "Blay", "sequence": "additional", "affiliation": []}, {"given": "Dominik", "family": "Ruettinger", "sequence": "additional", "affiliation": []}, {"given": "Carola H.", "family": "Ries", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2015, 1, 12]]}, "event": {"name": "Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; February 26 \u2014 March 1, 2014; San Diego, CA"}, "container-title": ["Innate Immune Cells in the Tumor Microenvironment"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.CHTME14-PR04", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T21:19:28Z", "timestamp": 1558214368000}, "score": 22.341883, "issued": {"date-parts": [[2015, 1, 1]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.CHTME14-PR04"], "URL": "http://dx.doi.org/10.1158/1538-7445.chtme14-pr04"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T19:32:11Z", "timestamp": 1574451131367}, "reference-count": 0, "publisher": "OMICS Publishing Group", "issue": "06", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J Cancer Sci Ther"], "published-print": {"date-parts": [[2011]]}, "DOI": "10.4172/1948-5956.s17-001", "type": "journal-article", "created": {"date-parts": [[2012, 2, 9]], "date-time": "2012-02-09T05:12:05Z", "timestamp": 1328764325000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Role of Tumor Suppressor Protein p53 in Apoptosis and Cancer Therapy"], "prefix": "10.4172", "volume": "03", "author": [{"given": "Naga", "family": "Deepthi CH", "sequence": "first", "affiliation": []}, {"given": "VVL Pavan", "family": "Kumar", "sequence": "additional", "affiliation": []}, {"given": "Ramesh", "family": "babu", "sequence": "additional", "affiliation": []}, {"given": "U Indirapriya", "family": "darshini", "sequence": "additional", "affiliation": []}], "member": "2674", "container-title": ["Journal of Cancer Science & Therapy"], "deposited": {"date-parts": [[2017, 9, 22]], "date-time": "2017-09-22T11:09:29Z", "timestamp": 1506078569000}, "score": 22.310276, "issued": {"date-parts": [[2011]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2011]]}, "issue": "06"}, "URL": "http://dx.doi.org/10.4172/1948-5956.s17-001", "ISSN": ["1948-5956"], "issn-type": [{"value": "1948-5956", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T23:40:27Z", "timestamp": 1574552427365}, "publisher-location": "New Delhi", "reference-count": 47, "publisher": "Springer India", "isbn-type": [{"value": "9788132208426", "type": "print"}, {"value": "9788132208433", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014]]}, "DOI": "10.1007/978-81-322-0843-3_24", "type": "book-chapter", "created": {"date-parts": [[2014, 10, 13]], "date-time": "2014-10-13T05:09:13Z", "timestamp": 1413176953000}, "page": "483-498", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Breast Cancer Therapy\u2013Classical Therapy, Drug Targets, and Targeted Therapy"], "prefix": "10.1007", "author": [{"given": "Eugenia Ch", "family": "Yiannakopoulou", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 8, 25]]}, "reference": [{"key": "24_CR1", "doi-asserted-by": "publisher", "first-page": "165", "DOI": "10.1586/era.12.172", "volume": "13", "author": "M Joerger", "year": "2013", "unstructured": "Joerger M, Th\u00fcrlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther. 2013;13:165\u201378.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "24_CR2", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1007/s00108-012-3156-9", "volume": "54", "author": "N Harbeck", "year": "2013", "unstructured": "Harbeck N, Wuerstlein R. Breast cancer [Individualized therapy concepts]. Internist (Berl). 2013;54:194\u20139. German.", "journal-title": "Internist (Berl)"}, {"key": "24_CR3", "doi-asserted-by": "publisher", "first-page": "1736", "DOI": "10.1093/annonc/mdr304", "volume": "22", "author": "A Goldhirsch", "year": "2011", "unstructured": "Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736\u201347.", "journal-title": "Ann Oncol"}, {"key": "24_CR4", "doi-asserted-by": "publisher", "first-page": "216", "DOI": "10.1186/1471-2407-12-216", "volume": "12", "author": "M Clavarezza", "year": "2012", "unstructured": "Clavarezza M, Mustacchi G, Casadei Gardini A, Del Mastro L, De Matteis A, Riccardi F, et al. Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer. 2012;12:216.", "journal-title": "BMC Cancer"}, {"key": "24_CR5", "doi-asserted-by": "publisher", "first-page": "142", "DOI": "10.1016/j.breast.2011.12.012", "volume": "21", "author": "M Khasraw", "year": "2012", "unstructured": "Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast. 2012;21:142\u20139.", "journal-title": "Breast"}, {"key": "24_CR6", "first-page": "26", "volume": "8", "author": "TK Yau", "year": "2005", "unstructured": "Yau TK. Cardiotoxicity after adjuvant anthracycline-based chemotherapy and radiotherapy for breast cancer. J HK Coll Radiol. 2005;8:26\u20139.", "journal-title": "J HK Coll Radiol"}, {"key": "24_CR7", "doi-asserted-by": "publisher", "first-page": "217", "DOI": "10.2165/00003495-200363020-00009", "volume": "63", "author": "AJ Wagstaff", "year": "2003", "unstructured": "Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217\u201336.", "journal-title": "Drugs"}, {"key": "24_CR8", "doi-asserted-by": "publisher", "first-page": "e53403", "DOI": "10.1371/journal.pone.0053403", "volume": "8", "author": "Q Li", "year": "2013", "unstructured": "Li Q, Jiang Y, Wei W, Yang H, Liu J. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8:e53403.", "journal-title": "PLoS One"}, {"key": "24_CR9", "first-page": "96", "volume": "1785", "author": "BT McGrogan", "year": "2008", "unstructured": "McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96\u2013132.", "journal-title": "Biochim Biophys Acta"}, {"key": "24_CR10", "doi-asserted-by": "publisher", "first-page": "516", "DOI": "10.1097/COC.0b013e3181b9cd52", "volume": "33", "author": "DL Toppmeyer", "year": "2010", "unstructured": "Toppmeyer DL, Goodin S. Ixabepilone, a new treatment option for metastatic breast cancer. Am J Clin Oncol. 2010;33:516\u201321.", "journal-title": "Am J Clin Oncol"}, {"key": "24_CR11", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.3109/07853890.2011.579151", "volume": "43", "author": "RH Alvarez", "year": "2011", "unstructured": "Alvarez RH, Valero V, Hortobagyi GN. Ixabepilone for the treatment of breast cancer. Ann Med. 2011;43:477\u201386.", "journal-title": "Ann Med"}, {"key": "24_CR12", "first-page": "176", "volume": "33", "author": "E Rivera", "year": "2010", "unstructured": "Rivera E. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes. Am J Clin Oncol. 2010;33:176\u201385.", "journal-title": "Am J Clin Oncol"}, {"key": "24_CR13", "doi-asserted-by": "publisher", "first-page": "513", "DOI": "10.2174/092986711794480177", "volume": "18", "author": "F Lumachi", "year": "2011", "unstructured": "Lumachi F, Luisetto G, Basso SM, Basso U, Brunello A, Camozzi V. Endocrine therapy of breast cancer. Curr Med Chem. 2011;18:513\u201322.", "journal-title": "Curr Med Chem"}, {"key": "24_CR14", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.2174/1574884711308020006", "volume": "8", "author": "PY Maximov", "year": "2012", "unstructured": "Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2012;8:135\u201355.", "journal-title": "Curr Clin Pharmacol"}, {"key": "24_CR15", "doi-asserted-by": "publisher", "first-page": "1687", "DOI": "10.1016/S0140-6736(05)66544-0", "volume": "365", "author": "Early Breast Cancer Trialists\u2019 Collaborative Group", "year": "2005", "unstructured": "Early Breast Cancer Trialists\u2019 Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687\u2013717. doi:\n                  10.1016/S0140-6736(05)66544-0\n                  \n                .", "journal-title": "Lancet"}, {"key": "24_CR16", "doi-asserted-by": "publisher", "first-page": "718", "DOI": "10.1634/theoncologist.11-7-718", "volume": "11", "author": "PD Ryan", "year": "2006", "unstructured": "Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist. 2006;11:718\u201331.", "journal-title": "Oncologist"}, {"key": "24_CR17", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1016/j.thromres.2011.11.025", "volume": "130", "author": "AA Onitilo", "year": "2012", "unstructured": "Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res. 2012;130:27\u201331.", "journal-title": "Thromb Res"}, {"key": "24_CR18", "doi-asserted-by": "publisher", "first-page": "766", "DOI": "10.1056/NEJMoa0810818", "volume": "361", "author": "H Mouridsen", "year": "2009", "unstructured": "Mouridsen H, Giobbie-Hurder A, Goldhirsch A. Letrozole alone or in sequence as adjuvant therapy. N Engl J Med. 2009;361:766\u201376.", "journal-title": "N Engl J Med"}, {"key": "24_CR19", "doi-asserted-by": "publisher", "first-page": "1802", "DOI": "10.1002/cncr.11745", "volume": "98", "author": "M Baum", "year": "2003", "unstructured": "Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802\u201310.", "journal-title": "Cancer"}, {"key": "24_CR20", "doi-asserted-by": "publisher", "first-page": "2131", "DOI": "10.1016/S0140-6736(02)09088-8", "volume": "359", "author": "M Baum", "year": "2002", "unstructured": "Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131\u20139.", "journal-title": "Lancet"}, {"key": "24_CR21", "doi-asserted-by": "publisher", "first-page": "1135", "DOI": "10.1016/S1470-2045(10)70257-6", "volume": "11", "author": "J Cuzick", "year": "2010", "unstructured": "Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135\u201341.", "journal-title": "Lancet Oncol"}, {"key": "24_CR22", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1016/S1470-2045(07)70385-6", "volume": "9", "author": "JF Forbes", "year": "2008", "unstructured": "Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45\u201353.", "journal-title": "Lancet Oncol"}, {"key": "24_CR23", "doi-asserted-by": "publisher", "first-page": "272", "DOI": "10.1177/1740774509105380", "volume": "6", "author": "A Giobbie-Hurder", "year": "2009", "unstructured": "Giobbie-Hurder A, Price K, Gelber R. Design, conduct, and analyses of Breast International Group (BIG) 1\u201398. A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009;6:272\u201387.", "journal-title": "Clin Trials"}, {"key": "24_CR24", "doi-asserted-by": "publisher", "first-page": "2747", "DOI": "10.1056/NEJMoa052258", "volume": "353", "author": "B Th\u00fcrlimann", "year": "2005", "unstructured": "Th\u00fcrlimann B, Keshaviah A, Coates AS, The Breast International Group (BIG) 1\u201398 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747\u201357.", "journal-title": "N Engl J Med"}, {"key": "24_CR25", "doi-asserted-by": "publisher", "first-page": "1213", "DOI": "10.1016/S0248-8663(01)00493-3", "volume": "22", "author": "E Lucchi-Angellier", "year": "2001", "unstructured": "Lucchi-Angellier E. Hormonoth\u00e9rapies et cancers du sein: mise au point. Rev Med Interne. 2001;22:1213\u201324. French.", "journal-title": "Rev Med Interne"}, {"key": "24_CR26", "first-page": "14", "volume": "22", "author": "PE Lonning", "year": "2004", "unstructured": "Lonning PE, Geisler J, Krag LE. Effect of exemestane on bone: a randomized placebo controlled study in postmenopausal women with early breast cancer at low risk. Proc Am Soc Clin Oncol. 2004;22:14.", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "24_CR27", "doi-asserted-by": "publisher", "first-page": "16", "DOI": "10.1038/sj.bjc.6602691", "volume": "9", "author": "J Lester", "year": "2005", "unstructured": "Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005;9:16\u201322.", "journal-title": "Br J Cancer"}, {"key": "24_CR28", "doi-asserted-by": "publisher", "first-page": "625", "DOI": "10.1007/s10549-011-1911-6", "volume": "132", "author": "S Singh", "year": "2012", "unstructured": "Singh S, Cuzick J, Mesher D, Richmond B, Howell A. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat. 2012;132:625\u20139.", "journal-title": "Breast Cancer Res Treat"}, {"key": "24_CR29", "doi-asserted-by": "publisher", "first-page": "1125", "DOI": "10.2165/11594170-000000000-00000", "volume": "34", "author": "M Younus", "year": "2011", "unstructured": "Younus M, Kissner M, Reich L, Wallis N. Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature. Drug Saf. 2011;34:1125\u201349.", "journal-title": "Drug Saf"}, {"issue": "Suppl 8", "key": "24_CR30", "first-page": "viii26", "volume": "18", "author": "EA Perez", "year": "2007", "unstructured": "Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007;18 Suppl 8:viii26\u201335.", "journal-title": "Ann Oncol"}, {"issue": "Suppl 6", "key": "24_CR31", "doi-asserted-by": "publisher", "first-page": "50", "DOI": "10.1007/s12325-011-0046-9", "volume": "28", "author": "J Cruz Jurado", "year": "2011", "unstructured": "Cruz Jurado J, Richart Aznar P, Garc\u00eda Mata J, Fern\u00e1ndez Mart\u00ednez R, Pel\u00e1ez Fern\u00e1ndez I, Sampedro Gimeno T, et al. Management of patients with metastatic breast cancer. Adv Ther. 2011;28 Suppl 6:50\u201365.", "journal-title": "Adv Ther"}, {"key": "24_CR32", "doi-asserted-by": "publisher", "first-page": "204", "DOI": "10.1016/j.clbc.2011.02.002", "volume": "11", "author": "A Howell", "year": "2011", "unstructured": "Howell A, Sapunar F. Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clin Breast Cancer. 2011;11:204\u201310.", "journal-title": "Clin Breast Cancer"}, {"key": "24_CR33", "doi-asserted-by": "publisher", "first-page": "819", "DOI": "10.1517/14740338.2011.595560", "volume": "10", "author": "SM Scott", "year": "2011", "unstructured": "Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011;10:819\u201326.", "journal-title": "Expert Opin Drug Saf"}, {"key": "24_CR34", "doi-asserted-by": "publisher", "first-page": "633", "DOI": "10.2165/00003495-200464060-00009", "volume": "64", "author": "K McKeage", "year": "2004", "unstructured": "McKeage K, Curran MP, Plosker GL. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs. 2004;64:633\u201348.", "journal-title": "Drugs"}, {"key": "24_CR35", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.3816/CBC.2008.n.037", "volume": "8", "author": "M Jahanzeb", "year": "2008", "unstructured": "Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008;8:324\u201333.", "journal-title": "Clin Breast Cancer"}, {"key": "24_CR36", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/S0140-6736(07)60028-2", "volume": "369", "author": "I Smith", "year": "2007", "unstructured": "Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29\u201336.", "journal-title": "Lancet"}, {"key": "24_CR37", "unstructured": "Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al., Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236\u201344.", "DOI": "10.1016/S1470-2045(11)70033-X", "doi-asserted-by": "crossref"}, {"issue": "Suppl 3", "key": "24_CR38", "doi-asserted-by": "publisher", "first-page": "S158", "DOI": "10.1016/S0960-9776(11)70316-2", "volume": "20", "author": "A Constantinidou", "year": "2011", "unstructured": "Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast. 2011;20 Suppl 3:S158\u201361.", "journal-title": "Breast"}, {"key": "24_CR39", "doi-asserted-by": "publisher", "first-page": "335", "DOI": "10.1517/14740331003627441", "volume": "9", "author": "AJ Chien", "year": "2010", "unstructured": "Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010;9:335\u201346.", "journal-title": "Expert Opin Drug Saf"}, {"issue": "Pt 2", "key": "24_CR40", "doi-asserted-by": "publisher", "first-page": "2332", "DOI": "10.1016/j.clinthera.2009.11.029", "volume": "31", "author": "AJ Tevaarwerk", "year": "2009", "unstructured": "Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31(Pt 2):2332\u201348.", "journal-title": "Clin Ther"}, {"key": "24_CR41", "doi-asserted-by": "publisher", "first-page": "405", "DOI": "10.1185/03007995.2013.775113", "volume": "29", "author": "B Boyraz", "year": "2013", "unstructured": "Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin. 2013;29:405\u201314.", "journal-title": "Curr Med Res Opin"}, {"key": "24_CR42", "doi-asserted-by": "crossref", "first-page": "1473", "DOI": "10.2119/molmed.2012.00302", "volume": "18", "author": "MF Barginear", "year": "2013", "unstructured": "Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med. 2013;18:1473\u20139.", "journal-title": "Mol Med"}, {"key": "24_CR43", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.2217/fon.13.7", "volume": "9", "author": "PF Peddi", "year": "2013", "unstructured": "Peddi PF, Hurvitz SA. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013;9:319\u201326.", "journal-title": "Future Oncol"}, {"key": "24_CR44", "doi-asserted-by": "publisher", "first-page": "w13231", "DOI": "10.4414/smw.2011.13231", "volume": "141", "author": "L Fang", "year": "2011", "unstructured": "Fang L, Barekati Z, Zhang B, Liu Z, Zhong X. Targeted therapy in breast cancer: what\u2019s new? Swiss Med Wkly. 2011;141:w13231. doi:\n                  10.4414/smw.2011.13231\n                  \n                .", "journal-title": "Swiss Med Wkly"}, {"key": "24_CR45", "doi-asserted-by": "publisher", "first-page": "1179", "DOI": "10.1016/S1470-2045(09)70315-8", "volume": "10", "author": "KL Jones", "year": "2009", "unstructured": "Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009;10:1179\u201387.", "journal-title": "Lancet Oncol"}, {"key": "24_CR46", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1007/s10549-009-0727-0", "volume": "122", "author": "A Valachis", "year": "2010", "unstructured": "Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122:1\u20137.", "journal-title": "Breast Cancer Res Treat"}, {"key": "24_CR47", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.1007/s40265-013-0034-2", "volume": "73", "author": "S Dhillon", "year": "2013", "unstructured": "Dhillon S. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs. 2013;73:475\u201385.", "journal-title": "Drugs"}], "container-title": ["Omics Approaches in Breast Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-81-322-0843-3_24", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 28]], "date-time": "2019-05-28T04:17:34Z", "timestamp": 1559017054000}, "score": 22.303719, "issued": {"date-parts": [[2014]]}, "ISBN": ["9788132208426", "9788132208433"], "references-count": 47, "URL": "http://dx.doi.org/10.1007/978-81-322-0843-3_24", "relation": {"cites": []}}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}